



(11)

**EP 1 757 686 A1**

(12)

**EUROPEAN PATENT APPLICATION**

published in accordance with Art. 158(3) EPC

(43) Date of publication:

**28.02.2007 Bulletin 2007/09**

(21) Application number: **04726750.5**

(22) Date of filing: **09.04.2004**

(51) Int Cl.:

**C12N 15/09** <sup>(2006.01)</sup> **C07K 16/28** <sup>(2006.01)</sup>  
**C07K 16/46** <sup>(2006.01)</sup> **A61P 35/00** <sup>(2006.01)</sup>  
**A61P 37/02** <sup>(2006.01)</sup> **A61P 43/00** <sup>(2006.01)</sup>  
**A61K 39/395** <sup>(2006.01)</sup>

(86) International application number:

**PCT/JP2004/005152**

(87) International publication number:

**WO 2005/100560 (27.10.2005 Gazette 2005/43)**

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HU IE IT LI LU MC NL PL PT RO SE SI SK TR**

(71) Applicants:

- **CHUGAI SEIYAKU KABUSHIKI KAISHA**  
Tokyo, 115-8543 (JP)
- **Ozaki, Shuji**  
Tokushima-shi, Tokushima 770-0804 (JP)
- **Abe, Masahiro**  
Tokushima-shi, Tokushima 770-0033 (JP)

(72) Inventors:

- **OZAKI, Shuji**  
Tokushima-shi, Tokushima 7700804 (JP)

- **ABE, Masahiro**  
Tokushima-shi, Tokushima 7700033 (JP)
- **TSUCHIYA, Masayuki,**  
**CHUGAI SEIYAKU KABUSHIKI K.**  
Gotenba-shi, Shizuoka 4128513 (JP)
- **KIMURA, Naoki,**  
**CHUGAI SEIYAKU KABUSHIKI KAISHA**  
Gotenba-shi, Shizuoka 4128513 3 (JP)
- **KAWAI, Shigeto,**  
**CHUGAI SEIYAKU KABUSHIKI KAISHA**  
Gotenba-shi, Shizuoka 4128513 (JP)

(74) Representative: **Vossius & Partner**

**Siebertstrasse 4**  
**81675 München (DE)**


(54) **CELL DEATH INDUCER**

(57) To identify antigens of the 2D7 antibody, the present inventors cloned the 2D7 antigen. As a result, the 2D7 antibody was found to recognize HLA class IA. In addition, the present inventors examined whether the 2D7 antibody has cell death-inducing activity. Nuclei fragmentation was observed when the 2D7 antibody was

cross-linked with another antibody, indicating that cell-death was induced. Further, diabodies of the 2D7 antibody were found to have very strong cell death-inducing activities, even without the addition of another antibody. These results indicate that minibodies of an HLA-recognizing antibody can be used as cell death-inducing agents.

**FIG. 10A**

**LEADER SEQUENCE**



**EP 1 757 686 A1**

FIG. 10B





FIG. 10C



**Description**Technical Field

5   **[0001]**   The present invention relates to minibodies that recognize HLA.

Background Art

10   **[0002]**   The HLA class I antigen is formed by a heterodimer of a 45-KD  $\alpha$  chain comprising three domains ( $\alpha 1$ ,  $\alpha 2$ ,  $\alpha 3$ ), and a 12-KD  $\beta 2$  microglobulin. The main role of the HLA molecule is to present CD8<sup>+</sup>T cells with antigenic peptides formed from about eight to ten amino acids and produced inside cells. As such, it plays a very important role in the immune response and immune tolerance induced by this peptide presentation.

15   **[0003]**   Cell growth-suppressing and cell death-inducing effects have been observed in lymphocytes upon HLA class IA antigen and antibody ligation, suggesting that HLA molecules may also be signal transduction molecules.

20   **[0004]**   More specifically, for example, there are reports showing cell growth suppression of activated lymphocytes by the B9.12.1 antibody against the  $\alpha 1$  domain of human HLA class IA, the W6/32 antibody against the  $\alpha 2$  domain, and the TP25.99 and A1.4 antibodies against the  $\alpha 3$  domain (Non-patent Documents 1, 2). Furthermore, two types of antibodies, MoAb90 and YTH862, against the human HLA class IA  $\alpha 1$  domain have been reported to induce apoptosis in activated lymphocytes (Non-patent Documents 2, 3, 4). Apoptosis induced by these two antibodies has been shown to be a caspase-mediated reaction (Non-patent Document 4), and therefore, HLA class IA antigens expressed in lymphocytes are also speculated to be involved in apoptosis signal transduction.

25   **[0005]**   Furthermore, the 5H7 antibody against the  $\alpha 3$  domain of human HLA class IA (Non-patent Document 5), and the RE2 antibody against the  $\alpha 2$  domain of mouse HLA class IA (Non-patent Document 6) have been also reported to induce cell death in activated lymphocytes and the like. However, in contrast with the aforementioned apoptosis-inducing antibodies MoAb90 and YTH862, it has been shown that none of the cell deaths induced by these antibodies are caspase-mediated. Accordingly, cell deaths due to 5H7 and RE2 are predicted to be of a type completely different from conventionally known apoptosis mechanisms.

30   **[0006]**   As described above, there are numerous reports of the cell growth-suppressing actions and cell death-inducing actions of anti-HLA antibodies. However, the antibodies used herein are all in the molecular forms of IgG antibodies, F(ab')<sub>2</sub>, or Fab, and to date there have been no reports that cell death-inducing activity is enhanced by reducing the molecular weight of antibodies, as in F(ab')<sub>2</sub> and Fab.

35   **[0007]**   Prior art literature relating to the present invention is shown below:

- [Non-patent Document 1] Fayen et al., Int. Immunol. 10: 1347-1358(1998)
- 40   [Non-patent Document 2] Genestier et al., Blood 90: 3629-3639 (1997)
- [Non-patent Document 3] Genestier et al., Blood 90: 726-735 (1997)
- [Non-patent Document 4] Genestier et al., J. Biol. Chem. 273: 5060-5066 (1998)
- [Non-patent Document 5] Woodle et al., J. Immunol. 158: 2156-2164 (1997)
- [Non-patent Document 6] Matsuoka et al., J. Exp. Med. 181: 2007-2015 (1995)
- 45   [Non-patent Document 7] Goto, et al. Blood 84: 1922 (1994)

Disclosure of the Invention

50   **[0008]**   The primary purpose of this invention is to provide minibodies of antibodies that recognize HLA class IA. A further objective of this invention is to provide novel therapeutic agents for tumors or autoimmune diseases that utilize these minibodies.

55   **[0009]**   The present inventors obtained 2D7 antibodies recognizing HLA class IA. Then, it was examined whether the 2D7 antibodies have cell death-inducing activity. More specifically, Jurkat cells were cultured in the presence or absence of 2D7, with anti-mouse IgG antibody also added. Cell nuclei were stained 48 hours later with Hoechst 33258, and then checked for cell nuclei fragmentation, which is characteristic of dead cells. As a result, hardly any cell death-inducing activity was observed in Jurkat cells with 2D7 antibody alone; however, nuclei fragmentation was observed when the antibody was further cross-linked with anti-mouse IgG antibody, showing that cell death was induced.

60   **[0010]**   As described, because cross-linking with an anti-mouse IgG antibody is necessary for 2D7 antibody to induce cell death, it is difficult to clinically apply the 2D7 antibody to tumors or autoimmune diseases. Therefore, the present inventors examined the effect of reducing the molecular weight of the 2D7 antibody on cell death induction. More specifically, genes encoding the variable regions of the 2D7 antibody were cloned from hybridomas. The 2D7 antibody was then made into diabodies using genetic engineering techniques and effects on cell death-inducing activity were examined. Surprisingly, the 2D7 antibody converted to diabodies showed strong cell death-inducing activity within a

very short time and at low doses, even without cross-linking with an anti-mouse IgG antibody. Furthermore, the diabody hardly acted on normal peripheral blood-derived lymphocytes and adherent cells, and specifically induced cell death in various myeloma cells, T cell leukemia cell lines, and activated lymphocytes. The above-mentioned results show that the minibodies of antibodies recognizing HLA can be utilized as cell death-inducing agents.

**[0011]** More specifically, the present invention provides the following [1] to [14]:

[1] a minibody, which comprises a heavy chain variable region comprising CDRs 1, 2, and 3 which consist of the amino acid sequences of SEQ ID NOs: 13, 14, and 15;

[2] a minibody which is functionally equivalent to the minibody of [1], and which comprises heavy chain CDRs consisting of amino acid sequences with one or more amino acid substitutions, deletions, insertions, and/or additions in the amino acid sequences of the heavy chain CDRs of the minibody of [1];

[3] a minibody, which comprises a light chain variable region comprising CDRs 1, 2, and 3 which consist of the amino acid sequences of SEQ ID NOs: 16, 17, and 18;

[4] a minibody which is functionally equivalent to the minibody of [3], and which comprises light chain CDRs consisting of amino acid sequences with one or more amino acid substitutions, deletions, insertions, and/or additions in the amino acid sequences of the light chain CDRs of the minibody of [3];

[5] a minibody, which comprises a heavy chain variable region comprising CDRs 1, 2, and 3 which consist of the amino acid sequences of SEQ ID NOs: 13, 14, and 15, and a light chain variable region comprising CDRs 1, 2, and 3 which consist of the amino acid sequences of SEQ ID NOs: 16, 17, and 18;

[6] a minibody which is functionally equivalent to the minibody of [5], and which comprises CDRs consisting of amino acid sequences with one or more amino acid substitutions, deletions, insertions, and/or additions in the amino acid sequences of the CDRs of the minibody of [5];

[7] the minibody of any one of [1] to [6], which is a diabody;

[8] a cell death-inducing agent comprising the minibody of any one of [1] to [7] as an active ingredient;

[9] the cell death-inducing agent of [8], which induces cell death of a B-cell or T-cell;

[10] the cell death-inducing agent of [9], wherein the B-cell or T-cell is an activated B-cell or an activated T-cell;

[11] a cell growth-suppressing agent comprising the minibody of any one of [1] to [7] as an active ingredient;

[12] an anti-tumor agent comprising the minibody of any one of [1] to [7] as an active ingredient;

[13] the anti-tumor agent of [12], wherein the tumor is blood tumor; and

[14] an agent for treating an autoimmune disease, wherein the agent comprises the minibody of any one of [1] to [7] as an active ingredient.

**[0012]** The present invention provides minibodies that recognize HLA. The minibodies of this invention are useful since their activity is elevated. Herein activity refers to a biological action that is caused by binding an antibody to an antigen. Specific examples include cell death-inducing actions, apoptosis-inducing actions, cell growth-suppressing actions, cell differentiation-suppressing actions, cell division-suppressing actions, cell growth-inducing actions, cell differentiation-inducing actions, cell division-inducing actions, and cell cycle-regulating actions. Cell death-inducing actions and cell growth-suppressing actions are preferred.

**[0013]** The cells that become the target of the above-mentioned actions, such as cell death-inducing actions and cell growth-suppressing actions, are not particularly limited, though blood cells and non-adherent cells are preferred. Specific examples of blood cells include lymphocytes (B cells, T cells), neutrophils, eosinophils, basophils, monocytes (preferably activated peripheral blood mononuclear cells (PBMC)), and myeloma cells, while lymphocytes (B cells, T cells), and myeloma cells are preferred, and T cells or B cells (particularly activated B cells or activated T cells) are most preferable. Non-adherent cells refer to cells that, when cultured, grow in a suspended state without adhering to the surface of culturing vessels of glass, plastic or the like. On the other hand, adherent cells refer to cells that, when cultured, adhere to the surface of culturing vessels of glass, plastic or the like.

**[0014]** In the present invention, administration of the minibodies that recognize HLA can treat or prevent diseases such as tumors, including blood tumors (hematopoietic tumors) (specific examples include leukemia, myelodysplastic syndrome, malignant lymphoma, chronic myelogenous leukemia, plasmacytic disorders (myeloma, multiple myeloma, macroglobulinemia), and myeloproliferative diseases (polycythemia vera, essential thrombocythemia, idiopathic myelofibrosis)), and autoimmune diseases (specific examples include rheumatism, autoimmune hepatitis, autoimmune thyroiditis, autoimmune bullous disease, autoimmune adrenocortical disease, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, autoimmune atrophic gastritis, autoimmune neutropenia, autoimmune orchitis, autoimmune encephalomyelitis, autoimmune receptor disease, autoimmune infertility, Crohn's disease, systemic lupus erythematosus, multiple sclerosis, Basedow's disease, juvenile diabetes, Addison's disease, myasthenia gravis, lens-induced uveitis, psoriasis, and Behcet's disease).

**[0015]** In the present invention, HLA refers to human leukocyte antigen. HLA molecules are categorized into class I and class II. Known examples of class I are HLA-A, B, C, E, F, G, H, J, and such; and known examples of class II are

HLA-DR, DQ, DP, and such. The antigens recognized by the antibodies of this invention are not particularly limited, so long as they are HLA molecules, preferably molecules classified as class I, and more preferably HLA-A.

**[0016]** In the present invention, a minibody comprises an antibody fragment that lacks a portion of a whole antibody (for example, whole IgG). The minibodies of the present invention are not particularly limited so long as they can bind an antigen. There are no particular limitations on the antibody fragments of the present invention, so long as they are portions of a whole antibody, and preferably contain a heavy chain variable region (VH) or a light chain variable region (VL). More preferably, the antibody fragments contain both a heavy chain variable region (VH) and a light chain variable region (VL). Specific examples of the antibody fragments include Fab, Fab', F(ab')<sub>2</sub>, Fv, and scFv (single chain Fv), but are preferably scFv (Huston, J. S. et al., Proc. Natl. Acad. Sci. U.S.A. (1988) 85, 5879-5883; Plickthun "The Pharmacology of Monoclonal Antibodies" Vol. 113, Resenburt and Moore Ed., Springer Verlag, New York, pp. 269-315, (1994)). Such antibody fragments can be prepared by treating an antibody with an enzyme, such as papain or pepsin for example, to generate antibody fragments, or by constructing genes that encode these antibody fragments, introducing them into expression vectors, and then expressing them in appropriate host cells (see, for example, Co, M. S. et al., 1994, J. Immunol. 152, 2968-2976; Better, M. and Horwitz, A. H., 1989, Methods Enzymol. 178, 476-496; Pluckthun, A. and Skerra, A., 1989, Methods Enzymol. 178, 497-515; Lamoyi, E., 1986, Methods Enzymol. 121, 652-663; Rousseaux, J. et al., 1986, Methods Enzymol. 121, 663-669; Bird, R. E. and Walker, B. W., 1991, Trends Biotechnol. 9, 132-137).

**[0017]** The minibodies of this invention preferably have smaller molecular weights than a whole antibody; however, they may form multimers, including dimers, trimers, and tetramers, and the molecular weights may become greater than that of the whole antibody.

**[0018]** A preferred minibody of this invention is an antibody comprising two or more antibody VHs and two or more antibody VLs, in which each of these variable regions is linked directly or indirectly via linkers and such. Such linkages may be covalent bonds or non-covalent bonds, or may be both. An even more preferable minibody is an antibody comprising two or more VH-VL pairs formed by non-covalent bonding between VH and VL. In this case, the distance between one VH-VL pair and another VH-VL pair is preferably shorter in a minibody than in a whole antibody.

**[0019]** A particularly preferable minibody of this invention is a diabody. A diabody is a dimer formed by binding two fragments, in which a variable region is linked to another variable region via a linker and such (for example, scFv) (hereinafter referred to as diabody-constituting fragments), and usually comprises two VLs and two VHs (P. Holliger et al., Proc. Natl. Acad. Sci. USA, 90, 6444-6448 (1993); EP404097; WO93/11161; Johnson et al., Method in Enzymology, 203, 88-98, (1991); Holliger et al., Protein Engineering, 9, 299-305, (1996); Perisic et al., Structure, 2, 1217-1226, (1994); John et al., Protein Engineering, 12(7), 597-604, (1999); Holliger et al., Proc. Natl. Acad. Sci. USA., 90, 6444-6448, (1993); Atwell et al., Mol. Immunol. 33, 1301-1312, (1996)). The bonds between the diabody-constituting fragments may be non-covalent or covalent bonds, but are preferably non-covalent bonds.

**[0020]** Alternatively, diabody-constituting fragments may be bound by a linker and such to form a single chain diabody (sc diabody). In such cases, linking the diabody-constituting fragments using a long linker of about 20 amino acids allows non-covalent bond formation between diabody-constituting fragments on the same chain, thus forming a dimer.

**[0021]** Diabody-constituting fragments include those with a linked VL-VH, linked VL-VL, and linked VH-VH, and are preferably those with a linked VH-VL. In the diabody-constituting fragments, the linker used to link a variable region to a variable region is not particularly limited, but is preferably a linker short enough to prevent non-covalent bonding between variable regions in the same fragment. The length of such a linker can be appropriately determined by those skilled in the art, and is ordinarily 2 to 14 amino acids, preferably 3 to 9 amino acids, and most preferably 4 to 6 amino acids. In this case, linkers between a VL and VH encoded on the same fragment are short, and thus a VL and VH on the same strand do not form a non-covalent bond nor a single-chain V region fragment; rather, the fragment forms a dimer with another fragment via non-covalent bonding. Furthermore, according to the same principle as in diabody construction, three or more diabody-constituting fragments may be bound to form multimeric antibodies, such as trimers and tetramers.

**[0022]** The present invention's minibodies recognizing HLA-A include minibodies that contain heavy chain variable regions comprising CDRs 1, 2, and 3 which consist of the amino acid sequences of SEQ ID NOs: 13, 14, and 15, respectively. Also included are minibodies that are functionally equivalent to the above minibodies and which comprise heavy chain CDRs consisting of amino acid sequences with one or more amino acid substitutions, deletions, insertions, and/or additions in the heavy chain CDR amino acid sequences of the above minibodies.

**[0023]** In addition, the minibodies of the present invention include minibodies that contain light chain variable regions comprising CDRs 1, 2, and 3 which consist of the amino acid sequences of SEQ ID NOs: 16, 17, and 18, respectively. Also included are minibodies that are functionally equivalent to the above minibodies and which comprise light chain CDRs consisting of amino acid sequences with one or more amino acid substitutions, deletions, insertions, and/or additions in the light chain CDR amino acid sequences of the above minibodies.

**[0024]** Preferred examples of the minibodies of the present invention include minibodies that contain heavy chain variable regions comprising CDRs 1, 2, and 3 which consist of the amino acid sequences of SEQ ID NOs: 13, 14, and 15, respectively, and light chain variable regions comprising CDRs 1, 2, and 3 which consist of the amino acid sequences

of SEQ ID NOs: 16, 17, 18.

**[0025]** Furthermore, preferred examples of the minibodies include minibodies that are functionally equivalent to the above-described minibodies and which comprise CDRs consisting of amino acid sequences with one or more amino acid substitutions, deletions, insertions, and/or additions in the CDR amino acid sequences of the above-described minibodies.

**[0026]** A particularly preferred minibody of the present invention include a diabody that comprises the following amino acid sequences: AspTyrPhelleHis (SEQ ID NO: 13) as heavy chain CDR1, TrpIlePheProGlyAspAspThrThrAsp-TyrAsnGluLysPheArgGly(SEQ ID NO: 14) as heavy chain CDR2, SerAspAspPheAspTyr (SEQ ID NO: 15) as heavy chain CDR3, SerAlaSerSerSerValSerTyrMetHis (SEQ ID NO: 16) as light chain CDR1, SerThrSerAsnLeuAlaSer (SEQ ID NO: 17) as light chain CDR2, and GlnGlnArgThrSerTyrProProThr (SEQ ID NO: 18) as light chain CDR3.

**[0027]** Herein, "functionally equivalent" means that the minibody of interest has an activity equivalent to that of a diabody of interest (for example, HLA-A binding activity, and cell death-inducing activity).

**[0028]** The number of mutated amino acids is not particularly limited, but may usually be 30 amino acids or less, preferably 15 amino acids or less, and more preferably five amino acids or less (for example, three amino acids or less). The amino acids are preferably mutated or modified in a way that conserves the properties of the amino acid side chain. Examples of amino acid side chain properties are: hydrophobic amino acids (A, I, L, M, F, P, W, Y, and V), hydrophilic amino acids (R, D, N, C, E, Q, G, H, K, S, and T), amino acids comprising the following side chains: aliphatic side chains (G, A, V, L, I, and P); hydroxyl-containing side chains (S, T, and Y); sulfur-containing side chains (C and M); carboxylic acid- and amide-containing side chains (D, N, E, and Q); basic side chains (R, K, and H); aromatic ring-containing side chains (H, F, Y, and W) (amino acids are represented by one-letter codes in parentheses). Polypeptides comprising a modified amino acid sequence, in which one or more amino acid residues is deleted, added, and/or replaced with other amino acids, are known to retain their original biological activities (Mark, D. F. et al., Proc. Natl. Acad. Sci. USA 81, 5662-5666 (1984); Zoller, M. J. & Smith, M. Nucleic Acids Research 10, 6487-6500 (1982); Wang, A. et al., Science 224, 1431-1433; Dalbadie-McFarland, G. et al., Proc. Natl. Acad. Sci. USA 79, 6409-6413 (1982)). In addition, the amino acid sequences of the antibody constant regions and such are well known to those skilled in the art.

**[0029]** In the present invention, the HLA-recognizing minibodies specifically bind to HLA. They are not particularly limited, so long as they have a biological action. The minibodies of this invention can be prepared by methods well known to those skilled in the art. For example, as described in the Examples, the antibodies can be prepared based on the sequence of an HLA-recognizing antibody (particularly sequences of the variable regions and sequences of CDRs), using genetic engineering techniques known to those skilled in the art.

**[0030]** For the sequence of the HLA-recognizing antibody, particularly of the framework region (FR), a well-known antibody sequence can be used, or an anti-HLA antibody can be prepared by a method well known to those skilled in the art using HLA as the antigen, and then the sequence of this antibody can be obtained and used. Specifically, for example, this can be performed as follows: HLA protein, or a fragment thereof, is used as a sensitizing antigen to perform immunizations according to conventional immunization methods, the obtained immunocytes are fused with well-known parent cells according to conventional cell fusion methods, and monoclonal antibody-producing cells (hybridomas) are then screened by ordinary screening methods. Antigens can be prepared by known methods, such as a method using baculoviruses (WO98/46777 and such). Hybridomas can be prepared, for example, according to the method of Milstein *et al.* (Kohler, G. and Milstein, C., Methods Enzymol. (1981) 73:3-46). When the antigen has low immunogenicity, immunization can be performed using the antigen bound to immunogenic macromolecules, such as albumin. Thereafter, cDNAs of the variable region (V region) of the antibody are synthesized from the mRNAs of the hybridomas using reverse transcriptase, and the sequences of the obtained cDNAs can be determined by known methods.

**[0031]** Antibodies that recognize HLA are not particularly limited, so long as they bind to HLA; mouse antibodies, rat antibodies, rabbit antibodies, sheep antibodies, human antibodies, and such may be used as necessary. Alternatively, artificially modified, genetically recombinant antibodies, such as chimeric and humanized antibodies, may be used to reduce heterologous antigenicity against humans. These modified antibodies can be produced using known methods. A chimeric antibody is an antibody comprising the variable regions of the heavy and light chains of an antibody from a non-human mammal such as a mouse, and the constant regions of the heavy and light chains of a human antibody. The chimeric antibody can be produced by linking a DNA encoding the variable regions of the mouse antibody with a DNA encoding the constant regions of the human antibody, incorporating this into an expression vector, and then introducing the vector to a host.

**[0032]** Humanized antibodies are also referred to as "reshaped human antibodies". Such humanized antibodies are obtained by transferring the CDR of an antibody derived from a non-human mammal, for example a mouse, to the CDR of a human antibody, and general gene recombination procedures for this are also known. Specifically, a DNA sequence designed to link a murine antibody CDR to the framework region (FR) of a human antibody can be synthesized by PCR, using primers prepared from several oligonucleotides containing overlapping portions of terminal regions. The obtained DNA is linked to a DNA encoding human antibody constant regions, and this is then integrated into an expression vector, and the antibody is produced by introducing this vector into host cells (see European Patent Application EP 239400,

and International Patent Application WO 96/02576). The human antibody FR to be linked via the CDR is selected so the CDR forms a favorable antigen-binding site. To form a suitable antigen-binding site in the CDR of the reshaped human antibody, amino acids in the framework region of the antibody variable region may be substituted as necessary (Sato, K. et al., 1993, Cancer Res. 53, 851-856).

**[0033]** These chimeric antibodies and humanized antibodies can be chimerized, humanized, and such after their molecular weight is reduced, or their molecular weight can be reduced after they have been chimerized, humanized, or such.

**[0034]** Methods for obtaining human antibodies are also known. For example, human lymphocytes can be sensitized *in vitro* with a desired antigen, or with cells expressing the desired antigen, and the sensitized lymphocytes can be fused with human myeloma cells, such as U266, to obtain the desired human antibody with antigen-binding activity (Examined Published Japanese Patent Application No. (JP-B) Hei 1-59878). Further, a desired human antibody can be obtained by using a desired antigen to immunize transgenic animals that have a full repertoire of human antibody genes (see International Patent Application WO 93/12227, WO 92/03918, WO 94/02602, WO 94/25585, WO 96/34096, and WO 96/33735). Furthermore, techniques for obtaining human antibodies by panning using a human antibody library are also known. For example, variable regions of human antibodies can be expressed as single chain antibodies (scFvs) on the surface of phages using phage display methods, and phages that bind to antigens can be selected. The DNA sequences that encode the variable regions of the human antibodies binding the antigens can be determined by analyzing the genes of the selected phages. By determining the DNA sequences of the scFvs that bind to the antigens, appropriate expression vectors carrying relevant sequences can be produced to yield human antibodies. These methods are already known, and are detailed in the following publications: WO 92/01047, WO 92/20791, WO 93/06213, WO 93/11236, WO 93/19172, WO 95/01438, and WO 95/15388.

**[0035]** Therefore, the minibodies of the present invention can be chimerized, humanized, or such by methods well known to those skilled in the art. Such chimeric and humanized antibodies are also included in the minibodies of this invention.

**[0036]** The antibodies of this invention may be conjugate antibodies that are bonded to various molecules, such as polyethylene glycol (PEG), radioactive substances, and toxins. Such conjugate antibodies can be obtained by performing chemical modifications on the obtained antibodies. Methods for antibody modification are established in this field. The term "antibody" in this invention includes such conjugate antibodies.

**[0037]** The present invention includes DNAs that encode the antibodies of this invention. This invention also includes DNAs encoding antibodies that hybridize under stringent conditions to the aforementioned DNAs, and have antigen-binding capacity and activity. Hybridization techniques (Sambrook, J. et al., Molecular Cloning 2nd ed., 9.47-9.58, Cold Spring Harbor Lab. press, 1989) are well known to those skilled in the art, and hybridization conditions can be selected appropriately by those skilled in the art. Such hybridization conditions include, for example, conditions of low stringency. Examples of conditions of low stringency include post-hybridization washing in 0.1x SSC and 0.1% SDS at 42°C, and preferably in 0.1x SSC and 0.1% SDS at 50°C. More preferable hybridization conditions include highly stringent conditions. Highly stringent conditions include, for example, washing in 5x SSC and 0.1% SDS at 65°C. In these conditions, the higher the temperature, the higher the expectation of efficiently obtaining DNAs with a high homology. However, several factors, such as temperature and salt concentration, can influence hybridization stringency, and those skilled in the art can suitably select these factors to achieve similar stringencies.

**[0038]** The DNAs of this invention are used for *in vivo* and *in vitro* production of the antibodies of this invention, and for other applications, such as gene therapy. The DNAs of this invention may be in any form, so long as they encode the antibodies of this invention. More specifically, they may be cDNAs synthesized from mRNAs, genomic DNAs, chemically synthesized DNAs, or such. Furthermore, the DNAs of this invention include any nucleotide sequence based on the degeneracy of the genetic code, so long as they encode the antibodies of this invention.

**[0039]** The antibodies of this invention can be produced by methods well known to those skilled in the art. More specifically, a DNA of an antibody of interest is incorporated into an expression vector. In so doing, the DNA is incorporated into the expression vector and expressed under the control of an expression regulatory region such as an enhancer or promoter. Next, antibodies can be expressed by transforming host cells with this expression vector. In this regard, appropriate combinations of hosts and expression vectors can be used.

**[0040]** The vectors include, for example, M13 vectors, pUC vectors, pBR322, pBluescript, and pCR-Script. In addition to the above vectors, for example, pGEM-T, pDIRECT, and pT7 can also be used for the subcloning and excision of cDNAs.

**[0041]** When using vectors to produce the antibodies of this invention, expression vectors are particularly useful. When an expression vector is expressed in *E. coli*, for example, it should have the above characteristics in order to be amplified in *E. coli*. Additionally, when *E. coli* such as JM109, DH5 $\alpha$ , HB101, or XL1-Blue are used as the host cell, the vector preferably has a promoter, for example, a lacZ promoter (Ward et al. (1989) Nature 341:544-546; (1992) FASEB J. 6: 2422-2427), araB promoter (Better et al. (1988) Science 240:1041-1043), or T7 promoter, to allow efficient expression of the desired gene in *E. coli*. Other examples of the vectors include pGEX-SX-1 (Pharmacia), "QIAexpress system" (QIAGEN), pEGFP, and pET (where BL21, a strain expressing T7 RNA polymerase, is preferably used as the host).

**[0042]** Furthermore, the vector may comprise a signal sequence for polypeptide secretion. When producing proteins into the periplasm of *E. coli*, the *pelB* signal sequence (Lei, S. P. et al. J. Bacteriol. 169:4379 (1987)) may be used as a signal sequence for protein secretion. For example, calcium chloride methods or electroporation methods may be used to introduce the vector into a host cell.

**[0043]** In addition to *E. coli*, expression vectors derived from mammals (e.g., pCDNA3 (Invitrogen), pEGF-BOS (Nucleic Acids Res. (1990) 18(17):5322), pEF, pCDM8), insect cells (e.g., "Bac-to-BAC baculovirus expression system" (GIBCO-BRL), pBacPAK8), plants (e.g., pMH1, pMH2), animal viruses (e.g., pHSV, pMV, pAdexLcw), retroviruses (e.g., pZIPneo), yeasts (e.g., "Pichia Expression Kit" (Invitrogen), pNV11, SP-Q01), and *Bacillus subtilis* (e.g., pPL608, pKTH50) may also be used as a vector for producing a polypeptide of the present invention.

**[0044]** In order to express proteins in animal cells such as CHO, COS, and NIH3T3 cells, the vector preferably has a promoter necessary for expression in such cells, for example, an SV40 promoter (Mulligan et al. (1979) Nature 277: 108), MMLV-LTR promoter, EF1ocpromoter (Mizushima et al. (1990) Nucleic Acids Res. 18:5322), CMV promoter, etc.). It is even more preferable that the vector also carry a marker gene for selecting transformants (for example, a drug-resistance gene enabling selection by a drug, such as neomycin and G418). Examples of vectors with such characteristics include pMAM, pDR2, pBK-RSV, pBK-CMV, pOPRSV, pOP 13, and such.

**[0045]** In addition, to stably express a gene and amplify the gene copy number in cells, CHO cells having a defective nucleic acid synthesis pathway can be introduced with a vector containing a DHFR gene (for example, pCHO1) to compensate for the defect, and the copy number may be amplified using methotrexate (MTX). Alternatively, a COS cell, which carries an SV40 T antigen-expressing gene on its chromosome, can be transformed with a vector containing the SV40 replication origin (for example, pCD) for transient gene expression. The replication origin may be derived from polyoma viruses, adenoviruses, bovine papilloma viruses (BPV), and such. Furthermore, to increase the gene copy number in host cells, the expression vector may contain, as a selection marker, an aminoglycoside transferase (APH) gene, thymidine kinase (TK) gene, *E. coli* xanthine guanine phosphoribosyl transferase (Ecogpt) gene, dihydrofolate reductase (*dhfr*) gene, and such.

**[0046]** Methods for expressing the DNAs of this invention in the bodies of animals include methods of incorporating the DNAs of this invention into appropriate vectors and introducing them into living bodies by, for example, a retrovirus method, liposome method, cationic liposome method, or adenovirus method. The vectors that are used include adenovirus vectors (for example, pAdexlcw), and retrovirus vectors (for example, pZIPneo), but are not limited thereto. General genetic manipulations such as inserting the DNAs of this invention into vectors can be performed according to conventional methods (Molecular Cloning, 5.61-5.63). Administration to living bodies can be carried out by *ex vivo* method or *in vivo* methods.

**[0047]** Furthermore, the present invention provides host cells into which a vector of this invention is introduced. The host cells into which a vector of this invention is introduced are not particularly limited; for example, *E. coli* and various animal cells are available for this purpose. The host cells of this invention may be used, for example, as production systems to produce and express the antibodies of the present invention. *In vitro* and *in vivo* production systems are available for polypeptide production systems. Production systems that use eukaryotic cells or prokaryotic cells are examples of *in vitro* production systems.

**[0048]** Eukaryotic cells that can be used include, for example, animal cells, plant cells, and fungal cells. Known animal cells include: mammalian cells, for example, CHO (J. Exp. Med. (1995)108, 945), COS, 3T3, myeloma, BHK (baby hamster kidney), HeLa, Vero, amphibian cells such as *Xenopus laevis* oocytes (Valle, et al. (1981) Nature 291, 358-340), or insect cells (e.g., Sf9, Sf21, and Tn5). CHO cells in which the DHFR gene has been deleted, such as *dhfr*-CHO (Proc. Natl. Acad. Sci. USA (1980) 77, 4216-4220) and CHO K-1 (Proc. Natl. Acad. Sci. USA (1968) 60, 1275), are particularly preferable for use as CHO cells. Of the animal cells, CHO cells are particularly favorable for large-scale expression. Vectors can be introduced into a host cell by, for example, calcium phosphate methods, DEAE-dextran methods, methods using cationic liposome DOTAP (Boehringer-Mannheim), electroporation methods, lipofection methods, etc.

**[0049]** Plant cells include, for example, *Nicotiana tabacum*-derived cells known as polypeptide production systems. Calluses may be cultured from these cells. Known fungal cells include yeast cells, for example, the genus *Saccharomyces*, such as *Saccharomyces cerevisiae*; and filamentous fungi, for example, the genus *Aspergillus* such as *Aspergillus niger*.

**[0050]** Bacterial cells can be used in prokaryotic production systems. Examples of bacterial cells include *E. coli* (for example, JM109, DH5 $\alpha$ , HB101 and such); and *Bacillus subtilis*.

**[0051]** Antibodies can be obtained by transforming the cells with a polynucleotide of interest, then culturing these transformants *in vitro*. Transformants can be cultured using known methods. For example, DMEM, MEM, RPMI 1640, or IMDM may be used as the culture medium for animal cells, and may be used with or without serum supplements such as fetal calf serum (FCS). Serum-free cultures are also acceptable. The preferred pH is about 6 to 8 over the course of culturing. Incubation is typically carried out at a temperature of about 30 to 40°C for about 15 to 200 hours. Medium is exchanged, aerated, or stirred, as necessary.

**[0052]** On the other hand, production systems using animal or plant hosts may be used as systems for producing polypeptides *in vivo*. For example, a DNA of interest may be introduced into an animal or plant, and the polypeptide



produced in the body of the animal or plant is then recovered. The "hosts" of the present invention include such animals and plants.

**[0053]** When using animals, there are production systems using mammals or insects. Mammals such as goats, pigs, sheep, mice, and cattle may be used (Vicki Glaser SPECTRUM Biotechnology Applications (1993)). Alternatively, the mammals may be transgenic animals.

**[0054]** For example, a DNA of interest may be prepared as a fusion gene with a gene encoding a polypeptide specifically produced in milk, such as the goat  $\beta$ -casein gene. DNA fragments containing the fusion gene are injected into goat embryos, which are then introduced back to female goats. The desired antibody can then be obtained from milk produced by the transgenic goats born from the goats that received the embryos, or from their offspring. Appropriate hormones may be administered to increase the volume of milk containing the polypeptide produced by the transgenic goats (Ebert, K.M. et al., Bio/Technology 12, 699-702 (1994)).

**[0055]** Insects, such as silkworms, may also be used. Baculoviruses carrying a DNA of interest can be used to infect silkworms, and the antibody of interest can be obtained from their body fluids (Susumu, M. et al., Nature 315, 592-594 (1985)).

**[0056]** When using plants, tobacco can be used, for example. When tobacco is used, a DNA of interest may be inserted into a plant expression vector, for example, pMON 530, and then the vector may be introduced into a bacterium, such as *Agrobacterium tumefaciens*. The bacteria are then used to infect tobacco such as *Nicotiana tabacum*, and the desired polypeptides are recovered from the leaves (Julian K.-C. Ma et al., Eur. J. Immunol. 24,131-138 (1994)).

**[0057]** The resulting antibodies of this invention may be isolated from the inside or outside (such as the medium) of host cells, and purified as substantially pure and homogenous antibodies. Any standard method for isolating and purifying antibodies may be used, and methods are not limited to any specific method. Antibodies may be isolated and purified by selecting an appropriate combination of, for example, chromatographic columns, filtration, ultrafiltration, salting out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, iso-electric focusing, dialysis, recrystallization, and others.

**[0058]** Chromatography includes, for example, affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration, reverse-phase chromatography, and adsorption chromatography (Strategies for Protein Purification and Characterization: A Laboratory Course Manual. Ed Daniel R. Marshak et al., Cold Spring Harbor Laboratory Press, 1996). These chromatographies can be carried out using liquid phase chromatographies such as HPLC and FPLC. The present invention also includes antibodies that are highly purified using these purification methods.

**[0059]** In the present invention, the antigen-binding activity of antibodies (Antibodies A Laboratory Manual. Ed Harlow, David Lane, Cold Spring Harbor Laboratory, 1988) can be measured using well known techniques. For example, ELISA (enzyme linked immunosorbent assay), EIA (enzyme immunoassay), RIA (radioimmunoassay), or fluoroimmunoassay may be used.

**[0060]** In the present invention, whether or not the antibodies of this invention induce cell death in non-adherent cells can be determined from whether cell death is induced in Jurkat cells or ARH77 cells, as in the Examples. Whether or not the antibodies induce cell death in adhesion cells can be determined from whether cell death is induced in HeLa cells, as in the Examples.

**[0061]** Furthermore, the present invention provides cell death-inducing agents or cell growth-suppressing agents which comprise minibodies or 2D7 antibodies of this invention as active ingredients. The cell death-inducing activity of the minibodies or 2D7 antibodies in this invention is considered to have a particularly large effect on activated T cells or B cells; therefore, it is considered to be particularly effective for treatment and prevention of tumors such as cancer (particularly blood tumors), and autoimmune diseases. Accordingly, the present invention provides methods of treatment and prevention of tumors such as cancer (particularly blood tumors), and autoimmune diseases that use the minibodies or 2D7 antibodies of this invention. When using 2D7 antibodies whose molecular weight has not been reduced as active ingredients, they are preferably cross-linked with an anti-IgG antibody and such.

**[0062]** The above-mentioned antibodies can also be used as conjugate antibodies, after linking to various reagents. Examples of such reagents include chemotherapy reagents, radioactive substances, and toxins. Such conjugate antibodies can be produced by known methods (US5057313, and US5156840).

**[0063]** The above-mentioned pharmaceutical agents can be directly administered to patients, or administered as pharmaceutical compositions formulated by known pharmaceutical methods. For example, they may be administered orally, as tablets, capsules, elixirs, or microcapsules, sugar-coated as necessary; or parenterally, in the form of injections of sterile solution or suspensions prepared with water or other pharmaceutically acceptable liquids. For example, they may be formulated by appropriately combining them with pharmaceutically acceptable carriers or media, more specifically, sterilized water or physiological saline solutions, vegetable oils, emulsifiers, suspending agents, surfactants, stabilizers, flavoring agents, excipients, vehicles, preservatives, binding agents, and such, and mixing them at a unit dosage form required for generally accepted pharmaceutical practice. The amount of active ingredient in the formulation is such that appropriate doses within indicated ranges are achieved.

**[0064]** Additives that can be mixed into tablets and capsules include, for example, binding agents such as gelatin,

cornstarch, tragacanth gum, and gum arabic; excipients such as crystalline cellulose; swelling agents such as cornstarch, gelatin, alginic acid; lubricants such as magnesium stearate; sweeteners such as sucrose, lactose, or saccharine; and flavoring agents such as peppermint and *Gaultheria adenothrix* oils, or cherry. When the unit dosage form is a capsule, liquid carriers, such as oils and fats, can be further included in the above-indicated materials. Sterile compositions to be injected can be formulated using a vehicle such as distilled water used for injection, according to standard protocols.

[0065] Aqueous solutions used for injections include, for example, physiological saline and isotonic solutions comprising glucose or other adjunctive agents such as D-sorbitol, D-mannose, D-mannitol, and sodium chloride. They may also be combined with appropriate solubilizing agents, such as alcohol, and specifically, ethanol, polyalcohol such as propylene glycol or polyethylene glycol, or non-ionic detergent such as polysorbate 80™ or HCO-50, as necessary.

[0066] Oil solutions include sesame oils and soybean oils, and can be combined with solubilizing agents such as benzyl benzoate or benzyl alcohol. Injection solutions may also be formulated with buffers, for example, phosphate buffers or sodium acetate buffers; analgesics, for example, procaine hydrochloride; stabilizers, for example, benzyl alcohol or phenol; or anti-oxidants. The prepared injections are typically aliquoted into appropriate ampules.

[0067] Administration to patients may be performed, for example by intra-arterial injection, intravenous injection, or subcutaneous injection, alternatively by intranasal, transbronchial, intramuscular, transdermal, or oral administration using methods well known to those skilled in the art. Doses vary depending on the body weight and age of the patient, method of administration and such; nevertheless, those skilled in the art can appropriately select suitable doses. Furthermore, if a compound can be encoded by a DNA, the DNA may be incorporated into a gene therapy vector to carry out gene therapy. Doses and administration methods vary depending on the body weight, age, and symptoms of patients, but, again, they can be appropriately selected by those skilled in the art.

[0068] A single dose of a pharmaceutical agent of this invention varies depending on the target of administration, the target organ, symptoms, and administration method. However, the usual dose for an adult (presuming a body weight of 60 kg) in the form of an injection is approximately 0.1 to 1000 mg, preferably approximately 1.0 to 50 mg, and more preferably approximately 1.0 to 20 mg per day, for example.

[0069] When administered parenterally, a single dose varies depending on the target of administration, the target organ, symptoms, and administration method. However, when in the form of an injection to an adult (presuming a body weight of 60 kg), usually it is considered advantageous to intravenously administer, for example, a single dose of about 0.01 to 30 mg, preferably about 0.1 to 20 mg, and more preferably about 0.1 to 10 mg per day. For other animals, a converted amount based on the amount for a body weight of 60 kg, or a converted amount based on the amount for a body surface area can be administered.

#### Brief Description of the Drawings

##### [0070]

Fig. 1 shows the adaptors used to produce the pMX2 vector. The bold letters indicate BstXI recognition sequences. Fig. 2A and Fig. 2B show 2D7 antigen expression in cell lines. Each cell type was stained with 2D7 antibody and the expression examined. (Solid line: no primary antibody; dotted line: 2D7 antibody)

Fig. 3 is a set of photographs showing the results of immunoprecipitation using the 2D7 antibody. NIH3T3, RPMI 8226, and U266 cells were solubilized, immunoprecipitation was performed with the 2D7 antibody, anti-BST-1 antibody (control), or protein G itself, and the proteins were detected by silver staining. In RPMI 8226 and U266, a molecule of approximately 12 KD (arrow), which is specifically precipitated by the 2D7 antibody, was detected. This band was cut out and peptide sequenced, and thus found to be  $\beta$ 2-microglobulin.

Fig. 4 shows flow diagrams for screening. Separation into pools, preparation of DNA, packaging into virus, infection of 3T3 cells, and screening using FACS were performed in one span (Fig. 4A). By the end of the fourth screening, the library was narrowed down to approximately 20 clones. In the fifth screening, 64 colonies were individually inoculated into a 96-well plate, pools were formed using the vertical and horizontal rows, and then screened. As a result, the library was narrowed down to twelve candidate clones (Fig. 4B).

Fig. 5 shows the results of screening using FACS. Fig. 5A shows the results of the second screening, Fig. 5B shows the results of the third screening, and Fig. 5C shows the results of the fourth screening. NIH3T3 cells were infected with retroviruses prepared from each pool, and three days later the cells were stained with the 2D7 antibody. The clones were narrowed down by gradually reducing the pool size of each screening.

Fig. 6 shows the results of screening using FACS. Fig. 6A shows the results of the fifth screening, and Fig. 6B shows the result of the final screening. As a result of the fifth screening, positive clones were found in rows 3, 4, 6, and 8, and in rows E, F, and G. As a result of screening the twelve candidate clones, positive clones were found in row E at 6E. When the nucleotide sequence of this 6E was analyzed, it was found to encode HLA class I A\*6802.

Fig. 7 is a graph and a set of photographs showing the influence on cells of the addition of 2D7 antibody. 2D7 antibody (10  $\mu$ g/ml) was added, and the number of viable cells was determined 48 hours later. Hardly any change

in cell growth was observed, even after 2D7 antibody was added (Fig. 7A). K562 cells (Fig. 7B), Jurkat cells (Fig. 7C), and RPMI8226 cells (Fig. 7D) were each observed 24 hours after 2D7 antibody addition. The 2D7 antibody induced aggregation of Jurkat cells.

Fig. 8 is a set of photographs showing cell death induction due to cross-linking of the 2D7 antibody. Each combination of the 2D7 antibody with anti-mouse IgG was made to act on Jurkat cells, and the cell nuclei were stained 48 hours later. Nuclear fragmentation due to cell death was observed when the 2D7 antibody and anti-mouse IgG acted on cells simultaneously.

Fig. 9 shows a 2D7 diabody (2D7DB) sequence. The nucleotide sequences in the figure is shown in SEQ ID NO: 3, and the amino acid sequence is shown in SEQ ID NO: 4.

Fig. 10A and Fig. 10B show a 2D7 diabody structure. Fig. 10C is a photograph showing 2D7 diabody transient expression in COS7 cells.

Fig. 11A and Fig. 11B show the cytotoxic activity of 2D7DB transiently expressed in COS7.

Fig. 12 shows the cytotoxic activity of 2D7DB transiently expressed in COS7. K562 cells (Fig. 12A) and Jurkat cells (Fig. 12B) were used.

Fig. 13 shows the cytotoxic activity of 2D7DB transiently expressed in COS7. RPMI 8226 cells (Fig. 13A), IL-KM3 cells (Fig. 13B), U266 cells (Fig. 13C), and ARH77 cells (Fig. 13D) were used.

Fig. 14 is a graph showing the growth-suppressing effect of purified 2D7DB.

Fig. 15 shows cell death induction by purified 2D7DB, 48 hours after induction. ARH77 cells (Fig. 15A), Jurkat cells (Fig. 15B), K562 cells (Fig. 15C), and HeLa cells (Fig. 15D) were used.

Fig. 16 shows cell death induction by purified 2D7DB, 48 hours after induction. U266 cells (Fig. 16A), and IL-KM3 cells (Fig. 16B) were used for the study.

Fig. 17 shows a time course of cell death induction by 2D7DB (2  $\mu$ g/ml). Cell death induction was investigated at 12 through to 38 hours. ARH77 cells (Fig. 17A) and Jurkat cells (Fig. 17B) were used.

Fig. 18 shows a time course of cell death induction by 2D7DB (2  $\mu$ g/ml). Cell death induction was investigated at three through to six hours. ARH77 cells (Fig. 18A) and Jurkat cells (Fig. 18B) were used.

Fig. 19 shows the effect of Z-VAD-FMK on cell death due to 2D7DB. The study was performed using ARH77 cells 16 hours after induction.

Fig. 20 shows the effect of Z-VAD-FMK on cell death due to 2D7DB. The study was performed using Jurkat cells 16 hours after induction.

Fig. 21 is a set of photographs showing that cell death due to 2D7DB is not accompanied by DNA fragmentation. The study was performed 24 hours after cell death induction.

Fig. 22 shows the results of investigating the effect of cytochalasin D on the cell death-inducing activity of 2D7DB. By pre-treating ARH77 cells with cytochalasin D, which is an actin-polymerization inhibitor, the cells showed resistance to 2D7DB-induced cell death.

Fig. 23 is a set of photographs showing the results of immunostaining to investigate the state of the intracellular actin and nuclei. After reacting ARH77 cells under the conditions described in the figure, actin was detected using anti-actin antibody (red), and cell nuclei were detected using Hoechst 33258 (blue). Actin was absent in cells treated with 2D7DB.

Fig. 24 shows that 2D7DB suppresses an increase in human IgG (hlgG) concentration in serum in a mouse model of human myeloma. The data shows the average  $\pm$  SEM. There was a significant difference (\*:  $p < 0.05$ ) between the vehicle-administered group and the 2D7DB-administered group, according to unpaired t-tests.

Fig. 25 shows that 2D7DB has a life-prolonging effect in a mouse model of human myeloma. There was a significant difference (\*:  $p < 0.05$ ) between the vehicle-administered group and the 2D7DB-administered group, according to generalized Wilcoxon tests.

Fig. 26 shows analyses of the action of 2D7DB on PBMC. PHA-M (Fig. 26A), ConA (Fig. 26B), and SAC (Fig. 26C) were used as mitogens. Fig. 26D shows the results in the absence of a mitogen, and Fig. 26E shows the results of a positive control (ARH77). The results shown are, from the top, those of no 2D7DB addition, three-hour addition, and 24-hour addition.

## Best Mode for Carrying out the Invention

**[0071]** Herein below, the present invention is specifically described using Examples; however, it should not to be construed as being limited thereto.

### **[1] Cell lines**

**[0072]** Human myeloma cell lines (RPMI8226, K562, and ARH77), human T-cell leukemia cell line (Jurkat), FDC-P1, HCI-16, and 2D7 hybridoma cell line (from University of Tokushima) were cultured in RPMI1640 medium (GIBCO BRL)

supplemented with 10% fetal calf serum (FCS). Human myeloma cell lines (IL-KM3 and U266) were individually cultured in the same medium supplemented with 2 ng/ml of IL-6 (R & D), and Ba/F3 was cultured in the same medium supplemented with 2 ng/ml of IL-3 (R & D). COS7, 293T, HeLa, NIH3T3, and BOSC23 were cultured in DMEM medium (GIBCO BRL) supplemented with 10% FCS, and CHO was cultured in  $\alpha$ -MEM medium (GIBCO BRL) supplemented with 5% FCS or 10% FCS.

## [2] Production of pMX2 vectors

**[0073]** The GFP gene region of the retrovirus vector, pMX-GFP, which packages the GFP gene into the virus particle, was cut out and removed using EcoRI-Sall. The adaptor, which comprised a BstXI site in its sequence (Fig. 1) (and was synthesized with an ABI DNA synthesizer, then annealed *in vitro* before use), was inserted into this region, forming pMX2.

## [3] Production of cDNA libraries

**[0074]** Total RNA was purified from RPMI8226 cells by standard methods using TRIzol (GIBCO BRL). Furthermore, the mRNAs were purified from 200  $\mu$ g of this total RNA, using  $\alpha$  MACS mRNA Isolation kit (Miltenyi Biotec) according to the manufacturer's instructions. The cDNAs were synthesized using random hexamers (SuperScript Choice System for cDNA Synthesis; Invitrogen) with 3.6  $\mu$ g of mRNA as template, and then a BstXI adaptor (Invitrogen) was linked to both ends. This cDNA was inserted into the pMX2 vector cleaved with BstXI, and was introduced into ELECTRO MAX DH10B (GIBCO BRL) by electroporation (2.5 KV, 200  $\Omega$ , 25  $\mu$ F). After adding 1 ml of SOC, the vectors were then incubated at 37°C for one hour, 1 ml of 40% glycerol/LB+Amp was added. A portion of the culture was used to check the titer and the remainder was stored at -80°C. The obtained library was plated at 200  $\mu$ l/well (7% DMSO/LB+Amp) into two 96-well plates, so that each well contained 1000 clones. These were cultured overnight at 37°C. Four wells (4000 clones) from this plate were combined and placed into an ampicillin-containing LB medium (4 ml). This was defined as one pool, the rest of the wells were treated similarly. Ultimately, 24 pools were prepared from a single plate. After incubating each pool overnight at 37°C, DNAs were prepared (QIAGEN) and used for transfection into packaging cells. The plates used for inoculation were stored at -80°C until use in secondary screening.

## [4] Purification of antibodies

**[0075]** 0.5 ml of ascites, sent from University of Tokushima, was adsorbed to a Protein A Hi Trap Affinity column (Amersham Pharmacia). The IgG fraction was then eluted using 0.1 M sodium citrate, pH3.0, and the 2D7 antibody was collected. This was concentrated using Centricon (YM-10; Millipore), and the buffer was exchanged to PBS to ultimately yield a total of 5.34 mg of antibody. This was separated into aliquots and stored at -20°C (concentration: 0.89  $\mu$ g/ $\mu$ L).

## [5] FACS

**[0076]** Adherent cells were detached using 1 mM EDTA/PBS, and non-adherent cells were collected by centrifugation, then suspended in FACS buffer (2.5% FCS, 0.02%  $\text{NaN}_3$ /PBS). These cells were left to stand on ice for one hour in a buffer (5% FCS/PBS) containing 2D7 antibody (final concentration 10  $\mu$ g/ml). These were then washed with FACS buffer, reacted in a solution of FITC-anti-mouse IgG (Immunotech) (1:150, 50  $\mu$ L FACS buffer) on ice for 30 minutes, washed twice with FACS buffer, and then analyzed using EPICS ELITE (COULTER).

## [6] Retrovirus infection

### (i) Retrovirus packaging

**[0077]** The day before transfection, 2ml of BOSC23 cells, which are retrovirus-packaging cells, were plated onto a 6-well plate at  $6 \times 10^5$  cells/well. Transfection was carried out by the following procedure: 1  $\mu$ g of the plasmid DNA derived from each pool was mixed with 3  $\mu$ L of FuGENE 6 Transfection Reagent (Roche), left to stand at room temperature for 20 minutes, and then added to the BOSC23 cell culture medium plated the day before. Cells were then cultured at 37°C for 48 hours, and the culture medium was collected. Dead cells were removed by centrifugation at 3000 rpm for five minutes, and the culture solution was then used as the virus solution.

### (ii) Virus infection

**[0078]** NIH3T3 cells plated onto 6-well plates ( $1 \times 10^5$  cells/2ml/well) the day before virus infection. Then 1 ml of virus solution supplemented with 10  $\mu$ g/ml of polybrene (hexadimethrine bromide; Sigma) was added to the wells and NIH3T3

cells were cultured for 24 hours. 1.5 ml of fresh medium was then added, the cells were cultured for another 48 hours, and gene expression was then analyzed using FACS.

[7] Immunoprecipitation

**[0079]** Cells were lysed in a lysis buffer (0.5% Nonidet P-40, 10 mM Tris, pH 7.6, 150 mM NaCl, 5 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 5 µg/ml aprotinin), and the resulting solution was centrifuged to remove the insoluble proteins and obtain a cell lysate. 1 µg of 2D7 antibody was added, and incubated at 4°C for four hours. Magnetic protein G (BioMag) was then added, and this was incubated for another one hour. Subsequently, the immunoconjugate was washed three times with a lysis buffer, and then subjected to SDS-PAGE. This gel was silver stained (Daichi Pure Chemicals) according to the attached instructions. For peptide sequencing, the gel on which SDS-PAGE was performed was transferred to ProBlott (Applied Biosystems), and this was stained for one minute with Coomassie blue staining solution (0.1% coomassie blue R-250 in 40% MetOH/1% acetic acid). After washing several times with 50% MetOH, the band of interest was cut out, washed five times with 1 ml of DDW, dried *in vacuo*, and then subjected to peptide sequencing.

[8] Cell growth assay using the 2D7 antibody

**[0080]** Each type of cell was plated into a 96-well plate at  $1 \times 10^6$  cells/ml in the presence or absence of PMA (50 ng/ml; GIBCO BRL) and PHA (10 µl/ml; GIBCO BRL). This was cultured for 48 hours after subsequent addition (10 µg/ml) or no addition of the 2D7 antibody. After culturing, morphological changes in the cells were observed under a microscope. The relative viable cell count was determined by adding WST-8 (viable cell count reagent SF; Nacalai Tesque), culturing at 37°C for two hours, and measuring OD<sub>450</sub>.

[9] Induction of cell death by cross-linking

**[0081]** Jurkat cells were plated on a 24-well plate at  $8 \times 10^5$  cells/well, and 10 µg/ml of anti-mouse IgG (Fc) antibody (Cappel) was further added in the presence (5 µg/ml) or absence of 2D7 antibody. 48 hours later, the cells were collected, and after washing with PBS, methanol was added to a concentration of 70%, and this was left to stand at -20°C for 15 minutes. After washing the cells several times with FACS buffer, Hoechst 33258 was added at a concentration of 10 µg/ml, and this was incubated at room temperature for 30 minutes. The cells were washed again with FACS Buffer, and an aliquot of the cells was then placed on a slide glass to observe the state of the nuclei under a fluorescence microscope.

[10] Cloning of the 2D7 variable region

**[0082]** Total RNA was purified from 2D7 hybridoma (provided by University of Tokushima) using TRIzol according to standard methods. Using 3 µg of this RNA as a template, cDNAs were synthesized using a SMART RACE cDNA Amplification kit (CLONTECH), according to the attached instructions. Using this cDNA as a template, the variable regions of the heavy chain and light chain were amplified by PCR using the following primers:

Heavy chain: 5'-CAGGGGCCAGTGGATAGACTGATG (SEQ ID NO: 7)

Light chain: 5'-GCTCACTGGATGGTGGGAAGATG (SEQ ID NO: 8)

The amplified cDNAs encoding each of variable regions were subcloned into pCR-TOPO vector (Invitrogen), and the nucleotide sequences (SEQ ID NOs: 1 and 2) were determined.

[11] Production of 2D7 diabody expression vector

**[0083]** Plasmids, to which each of the variable region cDNAs were subcloned, were used as templates, and the variable regions of the heavy chain and light chain (VH and VL) were respectively amplified using the primers below:

Heavy chain

2D7DB-H1: 5'-CCTGAATTCCACCATGCGATGGAGCTGGATCTTTC (SEQ ID NO: 9)

2D7DB-H2: 5'-AATTTGGCTACCGCCTCCACCTGAGGAGACTGTGAGAGTGGTGCCCT (SEQ ID NO: 10)

Light chain

2D7DB-L1: 5'-TCCTCAGGTGGAGGCGGTAGCCAAATTGTTCTACCCAGTCGCCAGC (SEQ ID NO: 11)

2D7DB-L2:

5'-ATTGCGGCCGCTTATCACTTATCGTCGTCATCCTTGTAGTCTTTTATCTCCAACCTTG  
TCCCCGAGCC (SEQ ID NO: 12)

[0084] Each of the VH and VL cDNAs amplified by these primers were combined into one tube, and further subjected to PCR. Using the PCR products as templates, PCR was performed again, this time using 2D7DB-H1 and 2D7DB-L2 as primers, to synthesize cDNA with VH and VL linked through a 5-mer linker (SEQ ID NO: 3). This cDNA was digested with EcoRI-NotI and inserted into the EcoRI-NotI gap of the animal cell expression vector, pCXND3. The nucleotide sequence was confirmed, completing the construction of the 2D7 diabody expression vector, pCXND3-2D7DB.

[12] Transient expression in COS7 cells

[0085] 2 µg of pCXND3-2D7DB, or of an empty vector used as a control, was mixed with 6 µL of transfection reagent (LT-1, MIRUS) according to the attached instructions, and this was added to COS7 cells (plated the day before into a 6-well plate at  $1 \times 10^5$  cells/well) whose medium had been exchanged to a serum-free medium (OPTI-MEM, GIBCO BRL). Five hours later, 200 µL of serum was added, and this was cultured for two to three days. The medium was collected, and dead cells were removed by centrifugation. The culture supernatant was then used for an experiment to detect cytotoxic activity.

[0086] Expression of 2D7DB in the culture supernatant was confirmed by Western blotting. More specifically, equal amounts of 2x SDS-PAGE Sample buffer and culture supernatant were added. In addition, after lysing the cells by adding a lysis buffer (0.5% Nonidet P-40, 10 mM Tris, pH 7.6, 150 mM NaCl, 5 mM EDTA), insolubilized proteins were removed by centrifugation to prepare a cell lysate, and an equal amount of 2x SDS-PAGE Sample buffer was added to this. After performing SDS-PAGE on each sample, the gels were transferred to PVDF membranes, and expression of the 2D7 single chain was detected using anti-FLAG antibody.

[13] Establishment of expression cell lines producing 2D7 diabody

[0087] 20 µg of pCXND3-2D7DB, linearized by cleaving with PvuI, was introduced to CHO cells (DXB11 strain) by electroporation, as described below.

[0088] After washing the CHO cells twice with ice-cold PBS, they were suspended in PBS at  $1 \times 10^7$  cells/ml. 20 µg of the above-mentioned plasmid was mixed into these cells, and this was electropulsed (1.5 KV, 25 µFD). The cells were diluted into appropriate fractions, plated on to a 10 cm dish, and cultured in the presence of G418 (GIBCO BRL) at a final concentration of 50 µg/ml. Approximately 30 clones were selected from the grown colonies, and the diabody expression levels in the culture supernatants were investigated by Western blotting. The clone with the highest expression level was expanded in a nucleic acid-free MEM $\alpha$  medium containing 5 nM MTX, and this was stocked as a high-producing cell line.

[14] Large-scale purification of 2D7 diabodies

[0089] A subconfluent 2D7DB-producing CHO cell line in a T-125 flask was detached using Trypsin-EDTA, and then this was transferred to a roller bottle (250 ml of MEM $\alpha$  without nucleotide + 5% FCS). Four days later, the culture solution was removed, and the cells were washed twice with PBS. The medium was then exchanged to 250 ml of CHO-S-SFMII medium (GIBCO BRL) to produce a serum-free medium, cells were cultured for three days, and then the cell culture supernatant was collected. This was filtered and used for purification after removing the dead cells by centrifugation.

[0090] Purification of single chain Fv was performed as follows: First, the collected culture supernatant was applied and adsorbed onto an anti-Flag M2 column. After washing with buffer A (50 mM Tris-HCl pH7.4, 150 mM NaCl, 0.01% Tween 20), single chain Fv was eluted with buffer B (100 mM Glycine pH3.5, 0.01% Tween 20). The collected sample was immediately neutralized with Tris-HCl pH8.0 so that the final concentration was 25 mM. This was then used for gel filtration purification by a Superdex 200HR (26/60) column. The dimer fraction of single chain Fv was collected in PBS containing 0.01 % Tween 20. A portion of the collected sample was subjected to SDS electrophoresis and silver staining to confirm that the protein of interest has been purified, and then this was concentrated to produce a purified 2D7 diabody preparation.

[15] Cell death induction experiment using 2D7 diabody

[0091] Various blood cell lines were plated into 24-well plates at  $2.5 \times 10^5$  cells/well. Purified 2D7DB, or the culture

supernatant of COS7 transiently expressing 2D7DB, was added and cell death was induced. When the culture supernatant of COS7 transiently expressing 2D7DB was used, the supernatant was added till its concentration was 50%. The amount of medium in each well was 0.8 to 1 ml/well. When stimulating Jurkat cells, Con A (WAKO) was added at the time of 2D7DB addition to a final concentration of 2 µg/ml.

**[0092]** Adherent cells (HeLa) were plated into a 6-well plate at  $2 \times 10^5$  cells/well, and the cells were attached by culturing overnight. Subsequently, purified 2D7DB was added to the culture solution.

**[0093]** Several hours to several days after 2D7DB addition, the non-adherent cells were collected as they were, and adherent cells were collected after detaching the cells with 1 mM EDTA/PBS. The cells were then washed with ice-cold PBS, and labeled with Annexin V, which is an apoptosis marker, and with PI, which is a dead-cell marker, according to the attached instructions (TACS Annexin V-FITC Apoptosis Detection Kit, TREVIGEN Instructions). The proportion of stained cells was then measured using flow cytometry (EPICS ELITE, COULTER).

[16] Cell death induction by Actinomycin D

**[0094]** Various blood cell lines were plated into 24-well plates at  $2-5 \times 10^5$  cells/well. To inhibit the initial stage of apoptosis, a caspase inhibitor (Z-VAD-FMK, Promega) was added at a final concentration of 50 µM, and after incubating for 2.5 hours, cell death was induced. For cell death induction by Actinomycin D, Actinomycin D (Sigma) was added at 1 µg/ml (Jurkat) or 5 µg/ml (ARH77), and for cell death induction by 2D7DB, 2 µg/ml of purified 2D7DB was added. Cells were collected 16 hours after cell death induction, and stained using Annexin V and PI.

[17] Cell growth assay using 2D7 diabody

**[0095]** Each type of cells was plated into a 96-well plate at a cell concentration of  $1-2 \times 10^4$  cells/well. 2D7DB was added at an appropriate concentration, and the cell count was determined after three days of culturing. Viable cell count was determined using WST-8. More specifically, this reagent was added to the cells at 10 µl/well, and the cells were then cultured at 37 °C for 1.5 hours. The relative viable cell count was determined by measuring the OD<sub>450</sub> using a spectrophotometer. The growth suppression rate was calculated from  $(1 - (\text{OD}_{450} \text{ of 2D7DB treated cells} / \text{OD}_{450} \text{ of 2D7DB untreated cells})) \times 100$ .

[18] Detection of DNA fragmentation

**[0096]** ARH77 and Jurkat cells were plated into a 6-well plate so that the cell concentration was  $2 \times 10^6$  cells/well, and cell death was induced by adding purified 2D7DB at a final concentration of 2 µg/ml, or Actinomycin D at a final concentration of 1 µg/ml (ARH77) or 5 µg/ml (Jurkat) to each well. The control was a well to which nothing was added. After culturing for 24 hours, the cells were collected, washed once with PBS, and then lysed in a lysis buffer (10 mM Tris pH7.5, 10 mM EDTA, 0.5% Triton X-100). This was followed by centrifugation to remove the insoluble proteins, and then the material was treated with RNase A and Proteinase K. A portion of this was then subjected to agarose gel electrophoresis to detect chromatin DNA fragmentation.

[19] Inhibition of cell death induction by cytochalasin D

**[0097]** ARH77 cells were plated into a 24-well plate to achieve a cell concentration of  $5 \times 10^5$  cells/well, and cytochalasin D (Sigma) was added to a final concentration of 20 µg/ml. The control was a well to which ethanol alone was added. After culturing for one hour, purified 2D7DB was added at various concentrations (0, 200, 500, 1000 ng/ml), and culturing was continued for another four hours. Cells were then collected, and the proportion of dead cells was detected by staining with PI.

[20] Immunostaining of 2D7DB-treated cells using anti-actin antibody

**[0098]** 2D7DB was added at a concentration of 1 µg/ml to cytochalasin D-treated/-untreated ARH77 cells, and after culturing at 37 °C for 15 minutes, the cells were adhered to a slide glass with a Cytospin. After immobilizing the cells by immersion in methanol for 15 minutes at -20 °C, blocking was performed using a blocking buffer (3% BSA/PBS) at 4 °C for one hour. This was then reacted with CY3-labeled anti-actin antibody (Sigma) diluted 100-fold in 1% BSA/PBS for one hour at room temperature, and then the cell nuclei were stained with Hoechst 33258. After washing several times with PBS, the cells were observed under a confocal laser scanning microscope (Olympus).

[Example 1] Expression analysis of 2D7 antigen in each type of cell line

**[0099]** To determine the cell line that should become the source to produce a cDNA expression library and the cell line that should become the host, 2D7 antigen expression in each type of animal cell was analyzed using FACS (Fig. 2A and Fig. 2B). As a result, among human-derived blood cells, extremely strong expression of the 2D7 antigen was observed in lymphocytic tumor cell lines, RPMI8226, U266, and in Jurkat, but expression was found to be weak in K562. In Ba/F3, FDC-P1, and HCl-16, which are blood cells derived from mice, expression was very weak, perhaps due to differences between species. Of the adherent cells, expression was observed in COS7, 293T, and HeLa. Expression was hardly observed in mouse NIH3T3 cells.

**[0100]** From the expression patterns mentioned above, RPMI8226 cells were judged to be appropriate as a cDNA library source to be used for expression cloning, and NIH3T3 cells were determined to be appropriate as host cells to be used for screening, to which the expression library is transferred.

[Example 2] Cloning of 2D7 antigen

[1] Cloning from a protein

**[0101]** Cell lysates were prepared from RPMI8226 cells and U266 cells, which express the 2D7 antigen, and NIH3T3 cells, which do not express the 2D7 antigen, and immunoprecipitation was performed using the 2D7 antibody. As a result, a molecule (approximately 12 kD) that precipitates specifically in RPMI8226 and U266 cells was observed (Fig. 3). This molecule was not detected by Western blotting using the 2D7 antibody, but since it is at least reproducibly precipitated by the 2D7 antibody, it was strongly predicted to be the 2D7 antigen itself, or a molecule that co-precipitates with the 2D7 antigen.

**[0102]** Coomassie staining was performed on this band; it was then cut out and the peptides were sequenced. As a result, this 12 kD molecule was identified as  $\beta$ 2 microglobulin ( $\beta$ 2M). Since  $\beta$ 2M is one of the class I MHC protein complexes that associate with HLA class I through non-covalent bonds, the 2D7 antibody is considered to have co-precipitated it as an HLA complex. HLA class I comprises the  $\alpha$ 1 and  $\alpha$ 2 domains required for antigen presentation, and the  $\alpha$ 3 domain which binds to  $\beta$ 2M. Since the 2D7 antibody can co-precipitate the  $\beta$ 2M molecule, it is anticipated that the 2D7 antibody will recognize the  $\alpha$ 1- $\alpha$ 2 domains of HLA class I as an epitope.

[2] Expression cloning of genes

**[0103]** cDNAs were synthesized using random hexamers from mRNAs purified from the 2D7 antigen-expressing cells, RPMI8226. These were inserted into a retrovirus vector, pMX2, and a retrovirus expression library was constructed. The library titer was investigated, and found to include a total of  $6 \times 10^6$  clones. Furthermore, the average cDNA length was found to be approximately 1.5 kb, arrived at by randomly selecting 24 clones from this library and investigating their insert size using colony PCR. Thus, the produced expression library was judged to be sufficient for use in expression cloning.

**[0104]** Fig. 4A and Fig. 4B show a flow diagram of the screening described below. In the first screening, 4000 independent clones were used in one pool, and 24 pools (corresponding to 96000 clones) were produced. The plasmids were packaged into retroviruses by transfecting each plasmid into BOSC23 cells. The resulting viruses derived from each pool were infected into NIH3T3 cells. Three days after infection, the cells were detached, and after staining with 2D7 antibody, expression analysis was performed using FACS. As a result, compared to NIH3T3 cells infected with viruses derived from an empty vector (control), 2D7-positive cells were found in 3 of the 24 pools (pools 4, 13, and 21).

**[0105]** Next, pools 4 and 13, which showed positive results in the first screening, were divided into four pools each comprising 1000 independent clones, and a second screening was performed. As a result, a single clearly positive pool was found from each pool (Fig. 5A, pool 4-4, and pool 13-1). Pool 13-1 was further divided into 21 pools, each comprising 160 independent clones, to perform a third screening. Two positive pools (Fig. 5B, 13-1-11 and 13-1-21) were identified. Subsequently, pool 13-1-11 was divided into eight pools, each comprising 20 clones, to perform a fourth screening, and a positive pool (Fig. 5C, 13-1-11-5) was obtained.

**[0106]** This pool was spread onto an LB plate, 64 colonies were picked one by one, and each of these were inoculated to one well of a 96-well plate. The eight clones in the vertical rows were taken as one pool to produce eight pools (1 to 8), and the eight clones in the horizontal rows were taken as one pool to produce eight pools (A to H), and a fifth screening was performed. As a result, pools 3, 4, 6, and 8, and pools E, F, and G were positive, thus narrowing down the positive candidate clones to twelve clones (Fig. 6A). FACS was performed on these twelve clones, and ultimately four positive clones (3F, 4G, 6E, and 8G) were identified as a single clone recognized by the 2D7 antibody (Fig. 6B).

**[0107]** As a result of reading the sequence of the insert portion of these clones, all four clones were found to be the full-length cDNA sequence of Human MHC class I HLA-A-6802.



**[0108]** HLA-A is classified into several dozen types of haplotypes. As a result of this cloning, the A\*6802 haplotype of HLA class I was identified as a 2D7 antigen, but since the 2D7 antibody recognizes a wide variety of cells, the haplotype of HLA class I in the RPMI8226 cells that were used as the gene source just happened to be A\*6802, and the 2D7 antibody was considered to be an antibody that recognizes any haplotype of HLA class I molecules.

[Example 3] Examination of growth inhibitory effect

**[0109]** Several types of leukemia cell lines (K562, Jurkat, and RPMI8226) were used to investigate whether the 2D7 antibody has a cytotoxic effect. The expression level of the 2D7 antigen in the three cell lines is: K562, weakly positive; Jurkat and RPMI8226, strongly positive.

**[0110]** K562 and Jurkat cells were plated in the presence or absence of PHA and PMA, and 10 µg/ml of the 2D7 antibody was added thereto. On observing the cells 24 hours later, weakly 2D7-positive K562 cells did not show obvious differences in their morphology due to the presence or absence of the 2D7 antibody, however, addition of 2D7 antibody resulted in significant cell aggregation in Jurkat cells strongly expressing 2D7 (Fig. 7B and Fig. 7C). However, growth inhibition due to addition of the 2D7 antibody was not observed (Fig. 7A). Growth inhibition due to 2D7 in Jurkat cells activated by PHA and PMA stimulation was also not observed.

**[0111]** Unexpectedly, addition of 2D7 antibody did not have an obvious effect on the morphology and growth of the strongly 2D7-positive RPMI8226 cells (Fig. 7D).

**[0112]** Next, it was examined whether cytotoxic effects can be observed by adding anti-mouse IgG(Fc) antibody to 2D7 antibody, to cross-link the antibodies. Anti-mouse IgG was added to Jurkat cells, in the presence or absence of 2D7 antibody. The cells were cultured, and 48 hours later the cell nuclei were stained with Hoechst33258. Cells were observed for fragmentation of cell nuclei, which is characteristic of dead cells (Fig. 8). As a result, nuclear fragmentation was observed in Jurkat cells by further cross-linking 2D7 with an antibody, indicating that cell death was induced.

[Example 4] Cloning of cDNA encoding the 2D7 antibody variable region, and the predicted diabody structure

**[0113]** Primers for the constant regions of the heavy chain and light chain of mouse IgG2b were produced, and DNA encoding the 2D7 variable region was cloned by 5'RACE method. The nucleotide sequences of the obtained PCR products are shown in SEQ ID NO: 1 and 2.

**[0114]** A single chain was then constructed based on these sequences. As shown in Fig. 9 and Fig. 10A, the 2D7 single chain is composed of the leader sequence of the heavy chain, the variable region of the heavy chain, and then across from a 5mer linker (GGGGS), the variable region of a light chain, followed by a cDNA (SEQ ID NO: 3) encoding a Flag-tag. Dimerization of this single chain may cause the 2D7 diabody to form the structure shown in Fig. 10B.

[Example 5] Analysis of the cytotoxic activity of the 2D7 diabody

(i) Cytotoxic activity of the 2D7 diabody transiently expressed in COS7

**[0115]** A 2D7 diabody expression vector was transfected into COS7 cells, and the culture supernatant was collected three days later. The culture supernatant and cell lysate were subjected to SDS-PAGE, and after performing Western blotting with an anti-Flag-tag antibody, a 2D7 single chain was found to be secreted in the culture supernatant (Fig. 10C).

**[0116]** This culture supernatant was added to Jurkat cells at a ratio of 50%. The percentage of dead cells was measured by staining the cells with PI and Annexin V a few days later. No significant change in the apoptosis marker was observed in Jurkat cells to which just the anti-BST-1 antibody and 2D7 antibody (5 µg/ml each) were added. Furthermore, no particular change could be observed when using the culture supernatant of COS7 transfected with the vector alone. On the other hand, cell death was clearly induced in Jurkat cells to which the culture supernatant of COS7 expressing 2D7DB was added (Fig. 11A and Fig. 11B).

**[0117]** Next, to investigate the HLA class I A-specific action of this 2D7DB, a similar experiment was performed using K562 cells, which are known to not express HLA class I A. As a result, 2D7DB had absolutely no influence on K562 cells, although it showed cell death inducing activity against Jurkat cells (Fig. 12A and Fig. 12B). This strongly supports the idea that the cell death inducing activity of 2D7DB is an action targeting HLA class I A, which is its epitope. Furthermore, according to each data, the sensitivity of Jurkat cells towards 2D7DB was found to be slightly higher in cells stimulated by con A.

**[0118]** Next, the action of 2D7DB on other myeloma cell lines was analyzed. RPMI8226, IL-KM3, U266, and ARH77 were incubated with a culture supernatant into which the vector alone was transfected (control), or with the 2D7DB-expressing COS7 culture supernatant. Two days later these cultures were double stained with Annexin V and PI, and analyzed using a flow cytometer. As a result, incubation with 2D7DB was found to significantly induce cell death in all of the cells (Fig. 13A to Fig. 13D).

## (ii) Cytotoxic activity of purified 2D7DB

**[0119]** The growth inhibitory effect of purified 2D7DB on each type of cell line (RPMI8226, ARH77, U266, and Jurkat) was analyzed. 2D7DB was added at 0, 0.5, 1.0, and 2.0  $\mu\text{g/ml}$ , and the number of cells was counted three days later.

**[0120]** Purified 2D7DB was then added, and 48 hours later, cells were stained with cell death markers, PI and Annexin V, and then analyzed. As in the results obtained when using 2D7DB transiently expressed in COS7, cell death was induced in Jurkat and ARH77 in a concentration-dependent manner, and K562 was not affected at all (Fig. 15A to Fig. 15C). Furthermore, 48 hours after the addition of 2D7DB to U266 and IL-KM3, significant cell death inducing activity was confirmed (Fig. 16A and Fig. 16B).

**[0121]** On the other hand, although the 2D7 antibody stained the adherent HeLa cells very well, 2D7DB had absolutely no influence under the same conditions (Fig. 15 D). This suggested that 2D7DB may act specifically on non-adherent cells, such as blood cells.

**[0122]** Next, the time taken for 2D7DB to induce cell death was analyzed. 2  $\mu\text{g/ml}$  of 2D7DB was added to ARH77 and Jurkat cells, cells were collected 12, 24, and 38 hours later, and stained with a cell death marker. The results showed that cell death was already induced in all cells twelve hours later (Fig. 17A and Fig. 17B). Therefore, cell death induction was investigated at earlier times (three and six hours). Surprisingly, it was shown that 2D7DB induces cell death at least within three hours after its addition (Fig. 18A and Fig. 18B). These results strongly support the idea that 2D7DB has a very strong cell death-inducing activity. Since 2D7DB strongly induces cell death, sufficient drug efficacy can be expected even with a short half life in the blood. Furthermore, safety becomes a concern if the whole antibody has strong cell death-inducing activity, considering the length of the half life in the blood; however, producing a diabody can overcome such problems.

**[0123]** Next, analyses were performed to determine whether cell death due to 2D7DB is induced through caspase activation, that is, whether it is apoptosis. As shown in Fig. 19 and Fig. 20, significant apoptosis was induced when ARH77 and Jurkat cells were treated with the apoptosis-inducing agent Actinomycin D, and then stained 16 hours later with Annexin V and PI. After pre-treating cells under these conditions with caspase inhibitor Z-VAD-FMK for 2.5 hours, apoptosis due to Actinomycin D was suppressed. However, cell death induced by 2D7DB was not inhibited at all by pretreatment with Z-VAD-FMK. These results show that 2D7DB induces cell death by a mechanism different from the ordinary caspase-mediated apoptosis mechanism.

**[0124]** To confirm this, fragmentation of chromatin DNA, known to be the most characteristic biochemical change accompanying apoptosis, was also analyzed.

**[0125]** ARH77 and Jurkat cells were treated with 2D7DB (2  $\mu\text{g/ml}$ ) or Actinomycin D, and DNAs were collected from the cells 24 hours later and subjected to electrophoresis (Fig. 21). As a result, DNA fragmentation characteristic of apoptosis was induced in all cells treated with Actinomycin D, which is an apoptosis-inducing agent. On the other hand, DNA fragmentation was not observed at all in 2D7DB-treated cells, even though the concentration of added 2D7DB was absolutely sufficient to induce cell death. These results also strongly support the idea that cell death due to 2D7DB is an unknown type of cell death, unaccompanied by the characteristics of apoptosis.

**[0126]** From the above-mentioned results, cell death due to 2D7DB was found to be caused by a pathway different from previously known cell death induction mechanisms. Therefore, further analysis was performed to elucidate the mechanism of cell death induction by 2D7DB. From the experiments described above, when 2D7DB was reacted with the cells, the cell membranes were often observed to be destroyed under the microscope. Therefore, 2D7DB was presumed to have some sort of influence on the actin skeleton. To examine this possibility, the cells were treated with an actin polymerization inhibitor (cytochalasin D), and then the influence of 2D7DB on cell death induction activity was analyzed.

**[0127]** Cytochalasin D (20  $\mu\text{g/ml}$ ) or ethanol alone (control) was added to ARH77 cells, and 1 hour later, 2D7DB was added at various concentrations. After a 4-hour incubation from the 2D7DB addition, cells were collected, PI staining was performed and the percentage of dead cells was measured (Fig. 22). As a result, pretreatment of cells with cytochalasin D was found to cause loss of sensitivity towards 2D7DB. These results suggested that 2D7DB causes some kind of effect on the cytoskeletal system such as actin to induce cell death by binding to HLA-class IA, which is the target molecule.

**[0128]** Therefore, cells treated with 2D7DB were stained by the actin antibody, and the dynamic change of the cytoskeletal system due to 2D7DB addition was analyzed visually. ARH77 cells were treated with 2D7DB, and 15 minutes later, the cells were immobilized with methanol, and the state of actin (red) in the cells was investigated by immunostaining (Fig. 23). As a result, compared to the image from those not treated with 2D7DB, significant destruction of the actin skeleton in the cell due to 2D7DB was observed.

**[0129]** The above-mentioned results strongly suggested that cell death due to 2D7DB may be caused by destruction of the actin skeleton in cells by 2D7DB bound to HLA class IA. This is a completely new type of cell death induction mechanism that has not been reported to date.

[Example 6] Drug efficacy test for 2D7 diabody using human myeloma animal model

(1) Production of mouse model for human myeloma

**[0130]** A mouse model of human myeloma was produced as follows. ARH 77 cells were prepared to reach  $2.5 \times 10^7$  cells/ml in RPMI1640 medium (GIBCO BRL) supplemented with 10% fetal calf serum (GIBCO BRL), and then 200  $\mu$ L of the above-mentioned ARH77 cell suspension ( $5 \times 10^6$  cells/mouse) was injected to SCID mice (male, 6 weeks old, Clea Japan) pretreated the day before with intraperitoneal administration of 0.2 mg of anti-asialo GM1 antibody (Wako Pure Chemicals) from the tail vein.

(2) Preparation of the antibody to be administered

**[0131]** On the day of administration, a 2D7 diabody was prepared at 0.8 mg/ml using filter-sterilized PBS(-), and this was used as the administration sample.

(3) Antibody administration

**[0132]** To the mouse model of human myeloma produced in (1), the administration sample prepared in (2) was administered through the tail vein at 10 ml/kg twice a day for 3 days from the first day after engraftment of ARH77 cells. As a negative control (vehicle), filter-sterilized PBS(-) was administered similarly at 10 ml/kg through the tail vein twice a day for 3 days. The antibody-administered group had 7 animals per group, and the vehicle-administered group had 8 animals per group.

(4) Human IgG assay of mouse serum

**[0133]** The quantity of human IgG produced by human myeloma cells in the mouse serum was determined by ELISA described below. 100  $\mu$ L of goat anti-human IgG antibody (BIOSOURCE) diluted to 1  $\mu$ g/ml with 0.1% bicarbonate buffer (pH9.6) was placed into a 96-well plate (Nunc), this was incubated at 4 °C overnight, and the antibody was immobilized. After blocking, mouse serum diluted in a stepwise manner, or as a standard, 100  $\mu$ L of human IgG (Cappel) was added, and this was incubated at room temperature for 1 hour. After washing, 100  $\mu$ L of a 5000-fold diluted alkaline phosphatase-labeled anti-human IgG antibody (BIOSOURCE) was added, and this was incubated at room temperature for 1 hour. After washing, substrate solution was added, and after incubation, absorbance at 405 nm was measured using MICRO-PLATE READER Model 3550 (BioRad), and the concentration of human IgG in mouse serum was calculated from the calibration curve obtained from the absorbance of the standard human IgG sample.

(5) Evaluation of anti-tumor effect

**[0134]** The anti-tumor effect of the 2D7 diabody on a human myeloma mouse model was evaluated using the change in the amount of human IgG (M protein) produced by the myeloma cells in mouse serum, and by the survival time. Regarding the change in human IgG level in mouse serum, serum was collected on the 24th day after transplanting the ARH77 cells, and the human IgG level was measured by the ELISA described above in (4). As a result, the level of human IgG (M protein) in the serum had increased in the vehicle-administered group to approximately 74  $\mu$ g/ml. In contrast, the level in the 2D7 diabody-administered group was significantly lower than in the control group ( $P < 0.005$ , unpaired t-test), and 2D7 diabody was shown to very strongly suppress the growth of ARH77 cells (Fig. 24). With regards to survival time, as shown in Fig. 25, the 2D7 diabody-administered group showed a significant increase in survival time compared to the vehicle-administered group.

**[0135]** Accordingly, the 2D7 diabody was shown to have an antitumor effect on the mouse model of human myeloma. The antitumor effect of the 2D7 diabodies of this invention may be based on the cell death-inducing action of this antibody.

[Example 7] Analysis of the action of 2D7DB on PBMC

**[0136]** The action of 2D7DB on human peripheral blood mononuclear cells (PBMCs) was analyzed. PBMCs were purified from the peripheral blood of a healthy adult volunteer by density gradient centrifugation. The PBMCs were plated at  $5 \times 10^5$  cells/1 ml/well onto a 24-well plate, in the presence or absence of a mitogen. Phytohemagglutinin M (PHA-M, Roche Diagnostics, final concentration: 10  $\mu$ g/ml), concanavalin A (ConA, Wako, final concentration: 10  $\mu$ g/ml), and SAC (Pansorbin Cells, Calbiochem, final concentration: 0.01 %) were used as mitogens. Cells were cultured in a 5% CO<sub>2</sub> incubator at 37 °C for three days. 24 or 3 hours before culture was complete, 2D7DB was added to yield a final concentration of 2  $\mu$ g/ml. After culture was complete, the cells were double stained with Annexin V and PI (Annexin V-

FITC Apoptosis Detection Kit I, Pharmingen), and then analyzed using a flow cytometer (EPICS XL, Coulter). As a positive control, ARH77 at  $2.5 \times 10^5$  cells/ml/well was cultured for 24 hours in the absence of a mitogen, and was reacted with 2D7DB, as for PBMC.

**[0137]** In the case of PBMC, the percentages of dead cells that were both Annexin V and PI-positive were 29%, 23%, and 25% in the absence of mitogens (in order: no addition, 3-hour addition, and 24-hour addition of 2D7DB; continued below); 20%, 45%, and 42% in the presence of PHA-M; 22%, 30%, and 34% in the presence of ConA; and 31%, 38%, and 40% in the presence of SAC (Figs. 26A to 26D). In the case of ARH77, the percentages were 16%, 56%, and 58% (Fig. 26E). These results showed that 2D7DB has hardly any effect on unstimulated PBMC, but induces cell death in a short time with mitogen-activated PBMC.

#### Industrial Applicability

**[0138]** This invention provides minibodies with high specific activities. By using these minibodies, adequate drug efficacy can be expected even with a short half-life. The minibodies of the present invention are further expected to be able to improve drug efficacy and to lower toxicity. In addition, since overall cost is reduced, including reduction of clinical dose and production cost, economical problems of concern in the development of antibody pharmaceuticals are also expected to improve.

## SEQUENCE LISTING

5  
<110> CHUGAI SEIYAKU KABUSHIKI KAISHA  
OZAKI Shuji  
10 ABE Masahiro

<120> Cell Death Inducer  
15

<130> C1-A0404P  
20

<160> 18

25 <170> PatentIn version 3.1

30 <210> 1  
<211> 547  
<212> DNA  
35 <213> Mus musculus

40 <400> 1  
tacgactcac tatagggcaa gcagtgggtat caacgcagag tacgogggga atctatgatc 60  
45 agtgtcctct ctacacagtc cctgacgaca ctgactccaa ccatgcgatg gagctggatc 120  
50 ttctcttcc tcctgtcaat aactgcaggt gtccattgcc aggtccagtt gcagcagtct 180  
55

EP 1 757 686 A1

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

ggacctgagc tggatgaagcc tggggcttca gtgaagatgt cttgtaagcc ttctggctac 240

accttcacag actactttat acaactgggtg aaacagaggc ctggacaggg acttgaatgg 300

attggatgga tttttcctgg agatgatact actgattaca atgagaagtt caggggcaag 360

accacactga ctgcagacaa atcctccagc acagcctaca ttttctcag cagcctgacc 420

tctgaggact ctgcgatgta tttctgtgta aggagtgcg actttgacta ctggggccag 480

ggcaccactc tcacagtctc ctgagccaaa acaacacccc catcagtcta tccactggcc 540

cctgctg 547

<210> 2

<211> 535

<212> DNA

<213> Mus musculus

<400> 2

ctaatacgac tcactatagg gcaagcagtg gtatcaacgc agagtacgcg gggactwatg 60

agaatagcag taattagcta gggaccaaaa ttcaaagaca aaatgcattt tcaagtgcag 120

attttcagct tcttgctaat cagtgcctca gtcacatgt ccagaggaca aattgtttctc 180

5        acccagtcgc cagcaatcat gtctgcatct ccaggggaga aggtcaccat aacctgcagt        240  
  
 10        gccagctcaa gtgtaagtta catgcactgg ttccagcaga agccaggcac ttttccaaa        300  
  
 15        ctctggattt atagcacatc caacctggct tctggagtcc ctactcgtt cagtggcagt        360  
  
 20        ggatctggga cctcttactc tctcacaatc agccgaatgg aggtgaaga tgctgccact        420  
  
 25        tattactgcc agcaaaggac gagttatcca cccacgttcg gctcggggac aaagttggag        480  
  
 30        ataaaacggg ctgatgctgc accaactgta tccatcttcc caccatccag tgagc        535

30        <210> 3

      <211> 789

      <212> DNA

35        <213> Artificial

40        <220>

      <223> an artificially synthesized DNA sequence

45        <220>

      <221> CDS

      <222> (14).. (775)

50        <223>

55

&lt;400&gt; 3

5 cctgaattcc acc atg cga tgg agc tgg atc ttt ctc ttc ctc ctg tca 49

Met Arg Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser

10 1 5 10

15 ata act gca ggt gtc cat tgc cag gtc cag ttg cag cag tct gga cct 97

Ile Thr Ala Gly Val His Cys Gln Val Gln Leu Gln Gln Ser Gly Pro

15 20 25

20 gag ctg gtg aag cct ggg gct tca gtg aag atg tct tgt aag gct tct 145

Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser

25 30 35 40

30 ggc tac acc ttc aca gac tac ttt ata cac tgg gtg aaa cag agg cct 193

Gly Tyr Thr Phe Thr Asp Tyr Phe Ile His Trp Val Lys Gln Arg Pro

45 50 55 60

35 gga cag gga ctt gaa tgg att gga tgg att ttt cct gga gat gat act 241

Gly Gln Gly Leu Glu Trp Ile Gly Trp Ile Phe Pro Gly Asp Asp Thr

40 65 70 75

45 act gat tac aat gag aag ttc agg ggc aag acc aca ctg act gca gac 289

Thr Asp Tyr Asn Glu Lys Phe Arg Gly Lys Thr Thr Leu Thr Ala Asp

50 80 85 90

55



**EP 1 757 686 A1**

	aaa tcc tcc agc aca gcc tac att ttg ctc agc agc ctg acc tct gag	337
5	Lys Ser Ser Ser Thr Ala Tyr Ile Leu Leu Ser Ser Leu Thr Ser Glu	
	95 100 105	
10	gac tct gcg atg tat ttc tgt gta agg agt gac gac ttt gac tac tgg	385
	Asp Ser Ala Met Tyr Phe Cys Val Arg Ser Asp Asp Phe Asp Tyr Trp	
15	110 115 120	
20	ggc cag ggc acc act ctc aca gtc tcc tca ggt gga ggc ggt agc caa	433
	Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Gly Gly Gly Gly Ser Gln	
	125 130 135 140	
25	att gtt ctc acc cag tcg cca gca atc atg tct gca tct cca ggg gag	481
	Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu	
30	145 150 155	
35	aag gtc acc ata acc tgc agt gcc agc tca agt gta agt tac atg cac	529
	Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met His	
	160 165 170	
40	tgg ttc cag cag aag cca ggc act ttt ccc aaa ctc tgg att tat agc	577
	Trp Phe Gln Gln Lys Pro Gly Thr Phe Pro Lys Leu Trp Ile Tyr Ser	
45	175 180 185	
50	aca tcc aac ctg gct tct gga gtc cct act cgc ttc agt ggc agt gga	625
	Thr Ser Asn Leu Ala Ser Gly Val Pro Thr Arg Phe Ser Gly Ser Gly	

EP 1 757 686 A1

190

195

200

5

tct ggg acc tct tac tct ctc aca atc agc cga atg gag gct gaa gat 673

Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu Asp

10

205 210 215 220

15

gct gcc act tat tac tgc cag caa agg acg agt tat cca ccc acg ttc 721

Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Thr Ser Tyr Pro Pro Thr Phe

225

230

235

20

ggc tcg ggg aca aag ttg gag ata aaa gac tac aag gat gac gac gat 769

Gly Ser Gly Thr Lys Leu Glu Ile Lys Asp Tyr Lys Asp Asp Asp Asp

25

240

245

250

30

aag tga taagcggccg caat 789

Lys

35

<210> 4

40

<211> 253

<212> PRT

<213> Artificial

45

<220>

50

<223> an artificially synthesized peptide sequence

55

&lt;400&gt; 4

5 Met Arg Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Ile Thr Ala Gly  
1 5 10 15

10 Val His Cys Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys  
20 25 30

15 Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe  
35 40 45

20 Thr Asp Tyr Phe Ile His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu  
50 55 60

25  
30 Glu Trp Ile Gly Trp Ile Phe Pro Gly Asp Asp Thr Thr Asp Tyr Asn  
65 70 75 80

35 Glu Lys Phe Arg Gly Lys Thr Thr Leu Thr Ala Asp Lys Ser Ser Ser  
85 90 95

40 Thr Ala Tyr Ile Leu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Met  
100 105 110

45 Tyr Phe Cys Val Arg Ser Asp Asp Phe Asp Tyr Trp Gly Gln Gly Thr  
115 120 125

50 Thr Leu Thr Val Ser Ser Gly Gly Gly Gly Ser Gln Ile Val Leu Thr  
55

EP 1 757 686 A1

130 135 140

5  
Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Ile  
145 150 155 160

10  
Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met His Trp Phe Gln Gln  
165 170 175

15  
Lys Pro Gly Thr Phe Pro Lys Leu Trp Ile Tyr Ser Thr Ser Asn Leu  
180 185 190

20  
Ala Ser Gly Val Pro Thr Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser  
195 200 205

25  
Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu Asp Ala Ala Thr Tyr  
210 215 220

30  
Tyr Cys Gln Gln Arg Thr Ser Tyr Pro Pro Thr Phe Gly Ser Gly Thr  
225 230 235 240

35  
Lys Leu Glu Ile Lys Asp Tyr Lys Asp Asp Asp Asp Lys  
245 250

40  
<210> 5  
<211> 29

45  
50  
55

<212> DNA

<213> Artificial

<220>

<223> an artificially synthesized adapter sequence

<400> 5

aattcccagc acagtggtag ataagtaag

29

<210> 6

<211> 29

<212> DNA

<213> Artificial

<220>

<223> an artificially synthesized adapter sequence

<400> 6

tcgacttact tatctaccac tgtgctggg

29

<210> 7

<211> 24

<212> DNA

<213> Artificial

5 <220>  
 <223> an artificially synthesized primer sequence

10 <400> 7  
 caggggccag tggatagact gatg 24

15

<210> 8  
 20 <211> 23  
 <212> DNA  
 <213> Artificial

25

<220>  
 30 <223> an artificially synthesized primer sequence

<400> 8  
 35 gctcactgga tggtaggaag atg 23

40

<210> 9  
 <211> 35  
 45 <212> DNA  
 <213> Artificial

50 <220>

55

<223> an artificially synthesized primer sequence

5

<400> 9

cctgaattcc accatgcgat ggagctggat ctttc

35

10

<210> 10

15

<211> 47

<212> DNA

20

<213> Artificial

<220>

25

<223> an artificially synthesized primer sequence

30

<400> 10

aatttggtta ccgcctccac ctgaggagac tgtgagagtg gtgcctt

47

35

<210> 11

40

<211> 47

<212> DNA

<213> Artificial

45

<220>

50

<223> an artificially synthesized primer sequence

55

<400> 11

5 tcctcaggtg gaggcggtag ccaaattggt ctcacccagt cgccagc 47

10 <210> 12

<211> 68

15 <212> DNA

<213> Artificial

20 <220>

<223> an artificially synthesized primer sequence

25 <400> 12

attgcggccg cttatcactt atcgctgca tcctttagt cttttatctc caactttgtc 60

30 cccgagcc 68

35 <210> 13

40 <211> 5

<212> PRT

<213> Mus musculus

45 <400> 13

Asp Tyr Phe Ile His

50 1 5

55



5

&lt;210&gt; 14

&lt;211&gt; 17

10

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

15

&lt;400&gt; 14

Trp Ile Phe Pro Gly Asp Asp Thr Thr Asp Tyr Asn Glu Lys Phe Arg

20

1

5

10

15

Gly

25

30

&lt;210&gt; 15

&lt;211&gt; 6

&lt;212&gt; PRT

35

&lt;213&gt; Mus musculus

40

&lt;400&gt; 15

Ser Asp Asp Phe Asp Tyr

1

5

45

50

&lt;210&gt; 16

&lt;211&gt; 10

55

<212> PRT

<213> Mus musculus

<400> 16

Ser Ala Ser Ser Ser Val Ser Tyr Met His

1 5 10

<210> 17

<211> 7

<212> PRT

<213> Mus musculus

<400> 17

Ser Thr Ser Asn Leu Ala Ser

1 5

<210> 18

<211> 9

<212> PRT

<213> Mus musculus

<400> 18

Gln Gln Arg Thr Ser Tyr Pro Pro Thr

1 5

## Claims

1. A minibody, which comprises a heavy chain variable region comprising CDRs 1, 2, and 3 which consist of the amino

acid sequences of SEQ ID NOs: 13, 14, and 15.

2. A minibody which is functionally equivalent to the minibody of claim 1, and which comprises heavy chain CDRs consisting of amino acid sequences with one or more amino acid substitutions, deletions, insertions, and/or additions in the amino acid sequences of the heavy chain CDRs of the minibody of claim 1.
3. A minibody, which comprises a light chain variable region comprising CDRs 1, 2, and 3 which consist of the amino acid sequences of SEQ ID NOs: 16, 17, and 18.
4. A minibody which is functionally equivalent to the minibody of claim 3, and which comprises light chain CDRs consisting of amino acid sequences with one or more amino acid substitutions, deletions, insertions, and/or additions in the amino acid sequences of the light chain CDRs of the minibody of claim 3.
5. A minibody, which comprises a heavy chain variable region comprising CDRs 1, 2, and 3 which consist of the amino acid sequences of SEQ ID NOs: 13, 14, and 15, and a light chain variable region comprising CDRs 1, 2, and 3 which consist of the amino acid sequences of SEQ ID NOs: 16, 17, and 18.
6. A minibody which is functionally equivalent to the minibody of claim 5, and which comprises CDRs consisting of amino acid sequences with one or more amino acid substitutions, deletions, insertions, and/or additions in the amino acid sequences of the CDRs of the minibody of claim 5.
7. The minibody of any one of claims 1 to 6, which is a diabody.
8. A cell death-inducing agent comprising the minibody of any one of claims 1 to 7 as an active ingredient.
9. The cell death-inducing agent of claim 8, which induces cell death of a B-cell or T-cell.
10. The cell death-inducing agent of claim 9, wherein the B-cell or T-cell is an activated B-cell or an activated T-cell.
11. A cell growth-suppressing agent comprising the minibody of any one of claims 1 to 7 as an active ingredient.
12. An anti-tumor agent comprising the minibody of any one of claims 1 to 7 as an active ingredient.
13. The anti-tumor agent of claim 12, wherein the tumor is blood tumor.
14. An agent for treating an autoimmune disease, wherein the agent comprises the minibody of any one of claims 1 to 7 as an active ingredient.

## FIG. 1

5' - AATT**CCAGCACAGTGG**TAGATAAGTAAG (SEQ ID NO: 5 )  
GGT**CGTGTCACC**ATCTATTCATCAGCT - 5' ( SEQ ID NO: 6 )

FIG. 2A




FIG. 2B




FIG. 3




FIG. 4A




FIG. 4B






FIG. 5A




FIG. 5B




FIG. 5C




FIG. 6A




FIG. 6B




FIG. 7A




FIG. 7B




FIG. 7C




FIG. 7D






FIG. 8

2D7(-) ANTI-MOUSE IgG (-) 2D7(-) ANTI-MOUSE IgG (+)



2D7(+) ANTI-MOUSE IgG (-) 2D7(+) ANTI-MOUSE IgG (+)



48



FIG. 10A




FIG. 10B




FIG. 10C




FIG.11A




FIG. 11B




FIG. 12A




FIG. 12B




FIG. 13A




FIG. 13B




FIG. 13C




FIG. 13D




FIG. 14






FIG. 15A




FIG. 15B




FIG. 15C




FIG. 15D




FIG. 16A




FIG. 16B




FIG. 17A




FIG. 17B




FIG. 18A




FIG. 18B




FIG. 19




FIG. 20






FIG. 21




FIG. 22




FIG. 23




FIG. 24




FIG. 25




FIG. 26A




FIG. 26B








FIG. 26C




FIG. 26D










FIG. 26E




File: Z0021208.LMD

Quad	% Total
UL	1.95
UR	15.84
LL	77.05
LR	5.16



File: Z0021207.LMD

Quad	% Total
UL	1.51
UR	55.82
LL	27.05
LR	15.62



File: Z0021206.LMD

Quad	% Total
UL	1.40
UR	57.54
LL	20.64
LR	20.42



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/JP2004/005152

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> Int.Cl <sup>7</sup> C12N15/09, C07K16/28, C07K16/46, A61P35/00, A61P37/02, A61P43/00, A61K39/395  According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) Int.Cl <sup>7</sup> C12N15/09, C07K16/28, C07K16/46, A61P35/00, A61P37/02, A61P43/00, A61K39/395  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) MEDLINE, BIOSIS/WPI(DIALOG), SwissProt/PIR/GeneSeq, Genbank/EMBL/DDBJ		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Hudson P.J. et al., High avidity scFv multimers; diabodies and triabodies, J.Immunol.Methods, 1999, Vol.231, pages 177 to 189	1-14
Y	Kortt A.A. et al., Dimeric and trimeric anti bodies: high avidity scFvs for cancer target ing, Biomol.Eng., 2001, Vol.18, pages 95 to 108	1-14
Y	Xiong D. et al., Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody, Cancer Lett., 2002, Vol.177, pages 29 to 39	1-14
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
Date of the actual completion of the international search 05 July, 2004 (05.07.04)		Date of mailing of the international search report 20 July, 2004 (20.07.04)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (January 2004)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/005152

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MATSUOKA S. et al., A novel type of cell death of lymphocytes induced by a monoclonal antibody without participation of complement, J.Exp.Med., 1995, Vol.181, pages 2007 to 2015	1-14
Y	Fayen J. et al., Negative signaling by anti-HLA class I antibodies is dependent upon two triggering events, Int.Immunol., 1998, Vol.10, pages 1347 to 1358	1-14
Y	Woodle E.S. et al., Anti-human class I MHC antibodies induce apoptosis by a pathway that is distinct from the Fas antigen-mediated pathway, J.Immunol., 1997, Vol.158, pages 2156 to 2164	1-14
Y	Tahtis k. et al., Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2), constructs in a breast carcinoma xenograft model, Clin.Cancer Res., 2001, Vol.7, pages 1061 to 1072	1-14
Y	Rossi E.A. et al., Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy, Clin.Cancer Res., 2003, Vol.9, pages 3886S to 3896S	1-14
E,X	WO 04/033499 A1 (Chugai Pharmaceutical Co., Ltd.), 22 April, 2004 (22.04.04), Full text (Family: none)	1-14

Form PCT/ISA/210 (continuation of second sheet) (January 2004)

## REFERENCES CITED IN THE DESCRIPTION

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

## Patent documents cited in the description

- EP 404097 A [0019]
- WO 9311161 A [0019]
- WO 9846777 A [0030]
- EP 239400 A [0032]
- WO 9602576 A [0032]
- JP 1059878 B [0034]
- WO 9312227 A [0034]
- WO 9203918 A [0034]
- WO 9402602 A [0034]
- WO 9425585 A [0034]
- WO 9634096 A [0034]
- WO 9633735 A [0034]
- WO 9201047 A [0034]
- WO 9220791 A [0034]
- WO 9306213 A [0034]
- WO 9311236 A [0034]
- WO 9319172 A [0034]
- WO 9501438 A [0034]
- WO 9515388 A [0034]
- US 5057313 A [0062]
- US 5156840 A [0062]

## Non-patent literature cited in the description

- FAYEN et al. *Int. Immunol.*, 1998, vol. 10, 1347-1358 [0007]
- GENESTIER et al. *Blood*, 1997, vol. 90, 3629-3639 [0007]
- GENESTIER et al. *Blood*, 1997, vol. 90, 726-735 [0007]
- GENESTIER et al. *J. Biol. Chem.*, 1998, vol. 273, 5060-5066 [0007]
- WOODLE et al. *J. Immunol.*, 1997, vol. 158, 2156-2164 [0007]
- MATSUOKA et al. *J. Exp. Med.*, 1995, vol. 181, 2007-2015 [0007]
- GOTO et al. *Blood*, 1994, vol. 84, 1922 [0007]
- HUSTON, J. S. et al. *Proc. Natl. Acad. Sci. U.S.A.*, 1988, vol. 85, 5879-5883 [0016]
- PLICKTHUN. *The Pharmacology of Monoclonal Antibodies*. Springer Verlag, 1994, vol. 113, 269-315 [0016]
- CO, M. S. et al. *J. Immunol.*, 1994, vol. 152, 2968-2976 [0016]
- BETTER, M. ; HORWITZ, A. H. *Methods Enzymol.*, 1989, vol. 178, 476-496 [0016]
- PLUCKTHUN, A. ; SKERRA, A. *Methods Enzymol.*, 1989, vol. 178, 497-515 [0016]
- LAMOYI, E. *Methods Enzymol.*, 1986, vol. 121, 652-663 [0016]
- ROUSSEAUX, J. et al. *Methods Enzymol.*, 1986, vol. 121, 663-669 [0016]
- BIRD, R. E. ; WALKER, B. W. *Trends Biotechnol.*, 1991, vol. 9, 132-137 [0016]
- P. HOLLIGER et al. *Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 6444-6448 [0019]
- JOHNSON et al. *Method in Enzymology*, 1991, vol. 203, 88-98 [0019]
- HOLLIGER et al. *Protein Engineering*, 1996, vol. 9, 299-305 [0019]
- PERISIC et al. *Structure*, 1994, vol. 2, 1217-1226 [0019]
- JOHN et al. *Protein Engineering*, 1999, vol. 12 (7), 597-604 [0019]
- HOLLIGER et al. *Proc. Natl. Acad. Sci. USA.*, 1993, vol. 90, 6444-6448 [0019]
- ATWELL et al. *Mol. Immunol.*, 1996, vol. 33, 1301-1312 [0019]
- MARK, D. F. et al. *Proc. Natl. Acad. Sci. USA*, 1984, vol. 81, 5662-5666 [0028]
- ZOLLER, M. J. ; SMITH, M. *Nucleic Acids Research*, 1982, vol. 10, 6487-6500 [0028]
- WANG, A. et al. *Science*, vol. 224, 1431-1433 [0028]
- DALBADIE-MCFARLAND, G. et al. *Proc. Natl. Acad. Sci. USA*, 1982, vol. 79, 6409-6413 [0028]
- KOHLER, G. ; MILSTEIN, C. *Methods Enzymol.*, 1981, vol. 73, 3-46 [0030]
- SATO, K. et al. *Cancer Res.*, 1993, vol. 53, 851-856 [0032]
- SAMBROOK, J. et al. *Molecular Cloning*. Cold Spring Harbor Lab. press, 1989, 9.47-9.58 [0037]
- WARD et al. *Nature*, 1989, vol. 341, 544-546 [0041]
- FASEB J., 1992, vol. 6, 2422-2427 [0041]
- BETTER et al. *Science*, 1988, vol. 240, 1041-1043 [0041]
- LEI, S. P. et al. *J. Bacteriol.*, 1987, vol. 169, 4379 [0042]
- *Nucleic Acids Res.*, 1990, vol. 18 (17), 5322 [0043]
- MULLIGAN et al. *Nature*, 1979, vol. 277, 108 [0044]
- MIZUSHIMA et al. *Nucleic Acids Res.*, 1990, vol. 18, 5322 [0044]
- *J. Exp. Med.*, 1995, vol. 108, 945 [0048]

## EP 1 757 686 A1

- **VALLE et al.** *Nature*, 1981, vol. 291, 358-340 [0048]
- *Proc. Natl. Acad. Sci. USA*, 1980, vol. 77, 4216-4220 [0048]
- *Proc. Natl. Acad. Sci. USA*, 1968, vol. 60, 1275 [0048]
- **EBERT, K.M. et al.** *Bio/Technology*, 1994, vol. 12, 699-702 [0054]
- **SUSUMU, M. et al.** *Nature*, 1985, vol. 315, 592-594 [0055]
- **JULIAN K.-C. MA et al.** *Eur. J. Immunol.*, 1994, vol. 24, 131-138 [0056]
- *Strategies for Protein Purification and Characterization: A Laboratory Course Manual*. Cold Spring Harbor Laboratory Press, 1996 [0058]
- *Antibodies A Laboratory Manual*. Cold Spring Harbor Laboratory, 1988 [0059]